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Cancer is one of the single largest cause of mortality in the U.S.A with 1 in every 3
individuals expected to develop cancer over their lifetimes1. The economic burden of cancer drugs
is estimated to reach $173 billion2 in the next two years. Despite enormous progresses in cancer
therapy, the mortality rate remains high due to the clinical challenges imposed by drug resistance
in tumor cells. The origin of drug resistance lies in the heterogeneity of tumors on the basis of
features such as cellular morphology, metabolism and mobility. Diversity in the tumor population
and the resulting clonal selection can eventually confer resistance and lead to the failure of targeted
therapy.
Tumor heterogeneity can be ascribed to multiple causes such as genetic mutations,
epigenetic changes and selective pressure from the tumor environment. A large number of
techniques, such as next-generation sequencing (NGS), can elucidate the genetic origins of
heterogeneity. Limited tools exist to dissect the epigenetic contributions. Accumulating literature,
as well as our own work, suggests that epigenetic modifications, such as DNA methylation and
modifications to its associated proteins, have a prominent role in modulating gene activity.
Elucidating the role of epigenetic marks on chromatin state and dissecting their phenotypic
contributions, are thus critically important to advance future cancer treatments.
In this work, we started by evaluating the roles of epigenetic modifications on chromatin
and their dynamic interactions with epigenetic enzymes. Built upon this fundamental knowledge,
novel tools were developed to track and sort cells based on their epigenetic traits individually and
combinatorially. Our sorting platform is compatible with high throughput applications and can
process 105 cells/min. The developed probes can sort heterogeneous cells into sub-populations
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based on the variability in their epigenetic background. A more robust picture of the spatial
distribution of modifications within the nucleus is provided by using a microscopy- based platform
to image the probes within live cells. The novel platforms developed in this work are used to
analyze the contributions of epigenetic modifications to tumor heterogeneity in breast cancer cells
and reveal the potential contributions of various epigenetic modifications in drug response and
tumor progression.
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1. INTRODUCTION

Motivation and Background
Intra-tumor heterogeneity (ITH) at the genetic, epigenetic and phenotypic level contributes
to the persistence and relapse of cancer. Heterogeneity can be observed in cellular morphology,
metabolism, proliferation, gene expression and metastatic potential, among other factors3,4. The
biological impact of tumor heterogeneity is seen mainly in (i) variations in tumor progression and
(ii) development of drug resistant cells. ITH prevails essentially in all cancer types and presents a
significant challenge in characterizing and treating tumors.
The origins of ITH can be classified into factors that are intrinsic and extrinsic to the cell.
Intrinsic factors are those that are inherent to the cell, such as genetic instability. Genetic mutations
occur stochastically in normal cells at the rate of 10-9 mutations per base pair per division; this rate
is elevated to 0.28-8.15 X 10-6 mutations per base per cell division in tumor cells5. Genetic
alterations such as single nucleotide polymorphism (SNP) and copy number variations (CNV) are
typical genetic contributors to ITH. Heritable changes in gene expression also arise from
epigenetic modifications, which do not alter the underlying DNA sequence6. Other driving factors
of intrinsic ITH are plasticity in gene expression7 and signal transduction8,9. Extrinsic factors that
contribute to ITH arise from the microenvironment of the tumor. In a diverse microenvironment,
several genotypes and phenotypes may be selected for or against, depending on their
spatiotemporal location in the tumor. Hypoxia, acidity, oxidative stress and the presence of
hormones define the complex microenvironment of a tumor and contribute to gene expression and
instability10,11. Finally, synergistic or predatory dynamics between the sub-populations of a tumor
can also drive growth12.
ITH has been historically assessed for several decades beginning with observations about
differences in the morphology of cancer cells13. Genetic heterogeneity has since been the primary
focus of studying ITH. By harnessing the potential of next-generation sequencing (NGS), it is now
possible to map the genetic diversity of tumors with single cell resolution. However, even in
genetically homogeneous tumors, significant variability is noticed in response to therapy. For
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instance, in tumors derived from a single cell of a non-small lung carcinoma, the majority of the
cells were drug sensitive, but a small sub-population of persistent cells was resistant to anticancer
agents14. Lineage tracking in genetic clones derived from colorectal cancer show similar variability
in proliferation and chemotherapy resistance15. Thus, even the mapping of the whole genome of a
single cell presents only a partial picture of ITH and its consequences.
An increasing number of studies have gradually emerged that highlight the presence of
epigenetic mechanisms in almost all facets of tumor heterogeneity. Beginning with tumor initiation
and progression, abnormalities in DNA methylation occur early in tumorigenesis and are present
in pre-malignant cells16,17, acting as a biomarker for early cancer detection18. DNA
hypermethylation occurs at certain focal regions of the genome in cancer cells, such as at tumor
suppressor genes, metastasis genes and DNA repair genes which can cumulatively affect
chromatin states and gene expression. Post translational modifications of histones are also
variously altered in the course of cancer19. Epigenetic modifications are also associated with cancer
stem cells, which are a population of cells with a long-term capability for self-renewal and
differentiation20. Epigenetic dynamics, such as gene promoter hypermethylation21,22 and bivalent
chromatin23 (containing both active and repressive marks) contribute to stem-cell like functionality.
Epigenetic changes also contribute to cellular plasticity since they are heritable modifications;
stochastically or aberrantly arising modifications can contribute to clonal selection, just as genetic
modifications. The emerging model of cellular plasticity, i.e. the epithelial to mesenchymal
transition (EMT) in cancer cells is controlled by epigenetic states24. The cumulative effect of
epigenetic heterogeneity arising from these factors results in variable response to therapy and
differential tumor potential.
Epigenetic and genetic changes influence each other strongly in the course of cancer
progression25. Evidence for epigenetic mechanisms as drivers of ITH is very limited, but a few
studies have emerged14,15,26 that point to an epigenetic origin of tumor heterogeneity in genetically
homogenous tumors. A clear understanding of the contributions of epigenetics to ITH is hampered
by the lack of tools to assay the epigenetic background of tumor cells with single cell resolution.
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While numerous studies have been conducted to understand ITH from a genetic perspective,
current methods are very limited in developing an epigenetic profile of ITH. Present models
quantifying the ITH of a bulk tumor sample provide a population average and potentially mask
rarer subpopulations of persistent cells. Genome wide single cell sequencing measurements have
provided valuable insights by overcoming some of the drawbacks of population average
measurements. For example, the identification of CNV27 and somatic mutations in single cells has
furthered understanding of the genetic evolution of breast cancer28. Single cell genetic ITH can
also be determined by DNA content, which is substantially altered in tumor cells. A flow cytometry
analysis which detects aneuploidy based on DNA staining has proven to be a powerful tool in
sorting highly intermixed populations of cells29,30 but provides limited molecular insights.
Similarly, profiling the heterogeneity in epigenetic background at the single cell level, can
outline the evolutionary history of tumors, predict patient outcomes and response to treatments.
Chromatin immunoprecipitation (ChIP)-Seq31 and whole genome bisulfide sequencing studies
have been carried out at the single cell level to probe the DNA methylation, histone modifications
and chromatin accessibility in cancer cell lines. However, these methods are time intensive, lack
temporal information, offer limited resolution and require specialized computational frameworks
for data interpretation32. Very limited technologies exist for the flow cytometric sorting of cells
based on their heterogeneous epigenetic backgrounds33,34. Most of the methods applicable to
epigenomic profiling of ITH are incompatible with live cell applications. However, since
modification levels are highly dynamic in evolution and response to drug treatments, valuable
information can be gained by tracking a single cell over time32. Additional efforts are thus required
towards the development of platforms for dynamic measurements of the epigenetic modifications
levels of single cells.

Thesis Goal and Outline
The main goal of this thesis was to develop a tool for the detection and sorting epigenetic
modifications in single cells. The enabling tool, along with advanced understanding of how
epigenetic modifications modulate chromatin structure and interact with specific “reader” domains,
will thus uniquely position us to dissect the contributions of epigenetics to tumor heterogeneity.
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To achieve this goal, we began by exploring the link between DNA modifications and
chromatin organization, both of which are significantly altered in cancer cells. The
hydroxymethylation of DNA at the C5 position of cytosine (5hmC) is an epigenetic mark that is
functionally opposite to DNA methylation. While extensive studies have been performed linking
DNA methylation to nucleosome formation and positioning, relatively little is known about 5hmC
in this context. In Chapter 2, we compared and contrasted both 5mC and 5hmC in their ability to
modulate the fundamental building block of the chromatin- the nucleosome. An in vitro approach
was used to quantify the effects of DNA methylation and hydroxymethylation on the compaction
and stability of a single nucleosome. We used three types of DNA with variable number of CpG
sites – (i) the strongly positioning Widom 601 DNA sequence and two variants containing (ii)
(CG)5 stretch at the central dyad of the nucleosome and (iii) five CpG dinucleotides at 10 bp
intervals. Modifications on DNA were introduced using modified nucleotides and nucleosomes
are formed by complexing the methylated or hydroxymethylated DNA with histone octamers.
Fluorescence lifetime spectroscopy (FLS) using FRET pairs on the DNA ends was performed to
determine the nucleosome stability. Competitive binding assays were used to determine the ease
of formation of nucleosomes from DNA containing either modification. Ours is the first study to
elucidate that 5hmC increases the binding affinity of DNA for the histone octamer and has varying
effects on the stability and compaction of nucleosomes depending on the CpG pattern and density.
DNA methylation itself is deposited and read by epigenetic “writer” and “reader” domains
such as DNA Methyltransferases (DNMT) and Methyl Binding Domain (MBD) family of proteins,
respectively. The binding of reader domains to sites of epigenetic modifications can modulate
chromatin architecture. In Chapter 3, we examined the binding characteristics of the MBD of
MBD1 in the context in which DNA is typically found within the nucleus, i.e. as nucleosomes. We
designed four DNA sequences with variable patterns and positions of methylated CpG sites and
assessed the binding of MBD1 to nucleosomes formed from different types of DNA. FRET based
measurements were used to quantify the conformational changes induced by MBD1 binding to
nucleosomes.
Towards achieving the central goal of this thesis, we developed recombinant protein probes
for the identification of DNA and histone methylation (H3K9me3 and H3K27me3). The binding

5
characteristics and selectivity of our probes were assessed by comparison with commercially
available antibodies. Epigenetic drugs were used to perturb the modification levels and the probes
were employed to quantify the relative change introduced. In Chapter 4, we tested the applicability
of the probes on a flow cytometry platform to allow rapid processing of millions of cells. We also
hoped to derive spatial information about the distribution and co-localization of the probes within
the nucleus which could not be obtained from flow cytometry data. We validated the use of
recombinant protein probes that selectively recognize H3K9me3 and 5mC. The probes were used
to quantify the epigenetic modification levels of model cell lines in a flow cytometry-based assay.
We used the probes to bin the cells into populations with variable epigenetic levels. The probes
were then introduced into a cancer cell line and used to sort the cells into bins of different DNA
and H3K9me3 levels, after which we quantified the drug response of each bin.
A microscopy-based approach was then tested to examine the spatial distribution and
amount of the epigenetic modifications within cells using the same probe sets. In Chapter 5, we
developed probes to trace the constitutive and facultative heterochromatin levels of live cells by
identifying the 5mC, H3K9me3 and H3K27me3 modifications. The modification levels were
perturbed using epigenetic drugs and confocal microscopy was used to quantify the extent of
change in heterochromatin. Combinatorial probes were used in a FRET based assay to provide
better spatial resolution and highlight areas of bivalent chromatin. we also compared the epigenetic
landscape of normal and cancer cell lines by evaluating the distribution of heterochromatin.
In Chapter 6, we highlight the key findings of this dissertation and provide some future
directions for applying the probes developed.

6

2. HYDROXYMETHYLATION OF DNA INFLUENCES NUCLEOSOME
CONFORMATION AND STABILITY IN VITRO

This chapter consists of a manuscript by Mendonca A, Chang E, Liu W and Yuan C that was
published in BBA-Gene Regulatory Mechanisms, 1839 (2014), 1323-1329.

Abstract
Hydroxymethylation of DNA at the C5 position of cytosine (5hmC) is recognized as an important
epigenetic mark that can play an important role in regulating gene transcription. However, the
molecular mechanism of gene regulation modulated by 5hmC is as yet unknown. In this study, we
examined the influence of 5hmC on nucleosomal dynamics. We quantitatively assessed the effects
of hydroxymethylation on nucleosome compactness, nucleosomal stability and the free energy of
DNA-histone binding. These findings have also been compared with another important epigenetic
mark, the cytosine methylation (5mC) of DNA. We observed that hydroxymethylation increases
the binding affinity of DNA for the histone octamer and is thus more likely to be incorporated into
nucleosomes. The formed nucleosome exhibits slightly different conformations based on the
sequence and epigenetic context of DNA. Furthermore, hydroxymethylation seems to decrease the
stability of formed nucleosomes in salt-induced dissociation processes, suggesting that once
formed, the 5hmC nucleosomes might be in an open and transcriptionally active state. This effect
was found to originate from the weakened interaction of hydroxymethylated DNA with the H2AH2B dimers. Our results reveal the effect of 5hmC on regulating nucleosome compactness and
stability.

Introduction
DNA methylation is a critical epigenetic modification that regulates a number of important
biological processes such as stem cell differentiation, X-chromosome inactivation and the
suppression of transposable elements 35,36. It is a modification that primarily occurs in CpG sites
and is associated with gene silencing and changes in chromatin structure37,38. The plasticity of the
methylation state as well as its potential reversal and regulation pathways have been extensively
studied in recent years39–41. It was found that the methylation state of DNA is dynamic and can be
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chemically modified by the Ten-Eleven Translocation (TET) proteins. TET proteins oxidize the
methyl group on the cytosine and convert it to a hydroxymethyl group at the C5 position of
cytosine (commonly known as 5hmC)42,43.
5hmC is an oxidative product derived from 5mC and is a potential intermediary in the
demethylation pathway42. The role of 5hmC in the demethylation process has been verified in brain,
zygotes and embryonic stem cells of mammals44–46. Accumulating evidence suggests that 5hmC,
apart from its role in demethylation, serves as an epigenetic modification, which can directly
regulate gene expression. For example, Mbd3 and Brg1 were found to regulate gene expression by
having Mbd3 bound specifically to 5hmC and regulate the nucleosome occupancy of promoter
regions 47.
The average 5hmC percentage across genome is approximately 0.1-0.7%, which is about
10-100 times less than what is typically observed for 5mC48,49. 5hmC is enriched and conserved
in important regulatory regions of genes, such as sequences near transcriptional starting sites,
promoters, exons and insulator binding sites50–52. Specifically, in embryonic stem cells, certain
CpG islands exhibit 5hmC of 3-24% in all CpG sites48.
Epigenetic modifications regulate gene expression by altering the structure and
functionality of chromatin. The nucleosome, consisting of 147 bp of DNA wrapped around a
histone octamer, is the fundamental building block of chromatin53. In vitro studies have shown that
DNA methylation can affect chromatin conformation by inducing changes in DNA rigidity54,
decreasing nucleosome-binding affinities55 and enhancing DNA end “breathing” motion56.
Histones also actively regulate the structure of nucleosomes57,58. Less is however known about the
effect of 5hmC. Compared to 5mC, 5hmC includes an additional hydroxyl group to cytosine at the
C5 position. This additional side chain can potentially increase the steric hindrance for nucleosome
formation, while the polarity of the hydroxyl group may also facilitate the nucleosome formation.
There is no experimental evidence detailing the effects of 5hmC on the chromatin conformation
and activity.
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This study aims to quantify the effect of 5hmC on nucleosomal formation, conformation,
and stability. We performed a side-by-side comparison of the effects of 5hmC and 5mC.
Specifically, we introduced methylation and hydroxymethylation to three different types of DNA
constructs, which differ on the basis of cytosine contents. The 5hmC percentage used in this study
is higher than what typically occurs in cells. We decided to use a high overall 5hmC level, because
it would allow us to unambiguously determine the overall effects of 5hmC. Additionally, the three
constructs we used in this study contain additional cytosine patterns in the form of a (CG)5 stretch
and a (CGX8)5 repeat, the most frequently observed CpG patterns in the genome59–61. The relative
differences in 5hmC levels among these three constructs are relatively small (< 3%). Consequently,
we will be able to assess how small changes in 5hmC levels impact the dynamic conformation of
nucleosome.
We characterized the ability of different DNA constructs to form nucleosomes using a
competitive nucleosome reconstitution assay. The role of 5hmC in altering nucleosome stability
and conformation was quantified using Förster Resonance Energy Transfer (FRET). Our results
show that 5mC decreases the binding affinity of DNA for histone octamers, while 5hmC
contrastingly increases the binding affinity. Methylation and hydroxymethylation can
differentially regulate the compactness of nucleosome, mainly through regulating DNA end
breathing motions, depending on its sequence context. Both modifications act to decrease the
stability of nucleosomes by potentially promoting dimer dissociation at increasing salt
concentrations. The seemingly contrasting observations in nucleosome-forming ability and
nucleosome-stability of 5hmC-containing DNA can be reconciled by the fact that 5hmC can
decrease the binding affinities of DNA to H2A-H2B dimers, while increasing DNA affinities to
H3-H4 tetramers.

Materials and Methods
2.3.1 Preparation of fluorescently labelled nucleosome samples
Three types of DNA constructs with different CpG patterns and cytosine densities were
used in this study. The detailed DNA sequences and alignments are included in Table 2.8.1 and
Fig 2.8.1. The sequences of these DNA fragments were derived from the 157bp Widom-601
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sequence, which has one of the highest known binding affinity to histone octamers 62,63. As DNA
wraps around a nucleosome, it has contact points with the octamer at 10 bp intervals53,64. We
therefore engineered two other sequences. These two additional sequences contain (i) an additional
(CG)5 stretch in the central dyad (later referred to as (CG)5) and (ii) five CpG dinucleotide repeats
at 10bp interval (later referred to as (CGX8)5), where X stands for any type of nucleotides,
respectively.
We used a PCR approach to incorporate methylated or hydroxymethylated cytosines in the
DNA fragment. Specifically, instead of using normal dCTP in dNTP mixtures, we utilized the
dNTP mixture containing methylated or hydroxymethylated dCTP (ZYMO Research). DNA
fragments containing either methylated or hydroxymethylated cytosines were amplified using a
label free DNA template and Taq DNA Polymerase (New England Biolabs). The DNA template
was custom synthesized (Genscript). For each DNA construct, we prepared three types of samples,
namely one control containing normal cytosines (control), one sample containing methylated
cytosines (5mC) and another sample containing 5-hydroxymethylcytosines (5hmC). These DNA
samples were fluorescently tagged using custom-made fluorescently labelled primers (Sigma).
For each DNA sample, we prepared three types of labelled DNA, (i) a donor-only sample
tagged with fluorescein (FAM, donor) (ii) a dual-labelled sample tagged with FAM (donor) and
Tetramethylrhodamine (TAMRA, acceptor), and (iii) an acceptor-only sample tagged with
TAMRA. The prepared DNA samples were analysed using a 6% polyacrylamide gel and were
purified using the same approach as we described previously65. A typical 6% gel of DNA samples
is shown in Fig. 2.8.2(A) and (B). The labelling efficiencies of the samples were calculated by
measuring the absorption spectra of the purified DNA fragments following an established
approach65. The FAM and TAMRA labelling efficiencies were consistently observed to be >~ 90%
and ~80% respectively across all the constructs.
Mono-nucleosomes were reconstituted by mixing DNA constructs with refolded
recombinant histone octamers at an optimized stoichiometric ratio as described before 65. Labelled
octamers used in alternative FRET studies were made by adding a FAM label to the serine 47 of
H4 converted to cysteine as described before 65. The reconstituted mono-nucleosome samples were

10
examined using a 5% polyacrylamide gel as shown in Fig. 2.8.3. All samples exhibited a single
translational setting and did not contain any unbound DNA fragments.
2.3.2 Time-domain fluorescence lifetime measurements
Förster Resonance Energy Transfer (FRET) was used to study the compactness of
nucleosomes by evaluating the end-to-end distance of nucleosomal DNA as shown in Fig. 2.4.2
inset. The FRET efficiency was calculated based on the following equation:
� =1−

,-.
,-

Eq.1

where �01 is the lifetime of the dual-labeled sample and �0 is the lifetime of the donor-only sample.
These fluorescence lifetimes were collected using a ChronosBH lifetime spectrometer (ISS) with
similar settings as described previously65. All measurements were performed using samples
prepared from > 3 independent reconstitutions.
Anisotropy values of single labelled samples (with either FAM or TAMRA) were collected
using a SpectraMax M5 Microplate Reader (Molecular Devices) at different salt concentrations
([KCl] ranging from 10-1150 mM). The collective anisotropy values are shown in Fig. 2.8.4. The
anisotropy values are found to be consistently below 0.25 and show little dependence on salt
concentrations or the type of cytosine modifications. The low anisotropy value suggests that the
fluorescent labels can be considered freely rotating under the examined experimental conditions.
Hindered rotation of dyes did not contribute to the observed changes in energy transfer efficiencies.
Ideally, the measured energy transfer efficiency values can be used to quantify the end-toend distance of nucleosomal DNA. The TAMRA labelling efficiencies of DNA samples, however,
was found to be less than 100% (~80%). Consequently, the energy transfer efficiencies will have
contributions from the existence of a small fraction of donor-only molecules. Therefore, we will
primarily use energy transfer efficiency (E) to assess the effects of 5hmC and 5mC on nucleosomal
conformation and stability, while commenting briefly on the actual distance information. Higher
E values correspond to a more compact nucleosome conformation.
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2.3.3 Competitive Nucleosome Reconstitutions
The binding affinities of all DNA constructs to histone octamers were quantitatively
examined using competitive nucleosome reconstitutions. The competitive reconstitutions were
performed following an established protocol66,67. In the reconstitution, unlabelled Widom-601 was
used as the competitor DNA and mixed with the TAMRA labelled DNA of interest as well as the
histone octamer. The competitor DNA concentration was kept at 3 µM, while the labelled DNA
concentration was kept at 0.04 µM. We used a constant octamer concentration of 2.5 µM and kept
the ratio of [octamer]: [DNA] as 0.85. This ratio was selected such that only a fraction of the
labelled DNA was bound to the histone octamer. The unmodified Widom-601 was used as a
reference DNA to calculate the relative changes in binding energy as ∆∆�2345 (kcal/mol).
Reconstituted samples were then analysed on a 5% native polyacrylamide gel and imaged
using a Kodak 4000R Imaging Station (Kodak). The intensities of the labelled DNA bands either
as free DNA or as nucleosomes were quantified using ImageJ. The relative change in binding
energy (∆∆�2345 ) was calculated following Eq. 2, similar as described by Thastrom et. al 67.
<=

∆∆�2345 = −�� ln (<

>?@

)

Eq. 2

where, �2 = ���������HIJ ⁄���������KHL and the reference is the Widom 601 unmodified DNA.
Higher ∆∆�2345 values indicate lower binding affinities.
Results
2.4.1 DNA modifications affect the histone octamer-binding affinity of DNA
We started by evaluating the binding affinities of various DNA constructs to histone
octamers. The binding affinities of DNA to histone octamers account for their likelihood of being
incorporated into nucleosomes and ultimately regulate chromatin structure by determining the
nucleosome-positioning pattern of chromatin

66,68

. We performed competitive nucleosome

reconstitutions to measure the free energy difference for nucleosome formation (∆∆�2345 ) based
on an established protocol66,67. Lower ∆∆�2345 values indicate a higher binding affinity and higher
probability of being occupied by nucleosomes.
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A typical gel analyzing the products from competitive nucleosome reconstitution is shown
in Fig. 2.4.1(A). The unmodified Widom-601 sequence was used as competitive sequences and
also reference DNA in our assay. At a selected DNA to octamer ratio (0.85), unmodified and
5hmC-containing DNA fragments both form a significant amount of nucleosomes. No nucleosome
formation, however, was observed for DNA fragments containing 5mC. This observation suggests
that DNA methylation significantly reduces the binding affinities of DNA to histone octamers
consistent with previous reports 69,70.

(A)

(B)

Figure 2.4.1: (A) Typical 5% polyacrylamide gel analyzing the competitive reconstitution
results. The unlabeled competitor DNA used in this assay was the Widom 601 sequence at a
concentration of 3 µM. The labelled DNA concentration was 0.04µM and the histone octamer
concentration was 2.5 µM. The [octamer]: [DNA] was 0.85. Three different sets of
reconstitutions were carried out for each of the three constructs. (B) Graph showing the ∆∆�2N
values obtained from > 3 independent reconstitutions (p<0.005 while comparing 5hmC and
control samples). Control: Widom 601 DNA.
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Using the same DNA to octamer ratio, both unmodified and hydroxymethylated DNA can
be incorporated into nucleosomes. We calculated ∆∆�2345 of these DNA fragments and the results
are summarized in Fig. 2.4.1(B). Unmodified Widom-601 sequence was used as reference DNA
and thus by definition has ∆∆�2345 equal to 0. Altering the sequences of DNA does not
significantly change its likelihood of forming nucleosomes. The unmodified Widom-601 sequence
exhibits the highest binding affinity among all unmodified constructs, consistent with literature
reports62. Converting cytosines to 5hmC significantly reduces ∆∆�2345 of the corresponding DNA
fragments. The changes are most significant for the DNA fragment containing additional CG
dinucleotides repeats, suggesting that the addition of 5hmC at 10bp intervals (the typical helical
repeat length of nucleosomal DNA64) can preferentially facilitate nucleosome formation.
2.4.2 DNA methylation and hydroxymethylation affect nucleosome compactness in a
sequence dependent manner
Once nucleosomes have been assembled, they continue to undergo conformational changes
depending on salt concentrations in vitro, which is a proxy for accessibility modulation in vivo 71–
75

. It has been shown that at low salt concentrations, i.e., [KCl] <200mM, nucleosomes assume a

fairly stable conformation and DNA-end breathing motion is the primary dynamic feature of the
protein-DNA complex65,71,76–78. This end breathing motion is thought to control accessibility of
DNA. We thus examined the dynamic conformation of nucleosomes under two salt concentrations,
namely [KCl]=10 mM and 100 mM, close to the physiological condition.
A FRET pair (FAM/TAMRA) was introduced to the 5’ ends of nucleosomal DNA as
shown in Fig. 2.4.2 inset. The measured energy transfer efficiencies (E), therefore, characterize
the relative compactness of formed nucleosomes. The results obtained at 10 and 100mM [KCl] are
illustrated in Fig. 2.8.5 and Fig. 2.4.2 respectively. We first examined the sequence dependence
of the measured E. The Widom-601, (CG)5 and (CGX8)5 constructs exhibit decreasing values of
E, indicating more open conformations. The difference is most pronounced between Widom-601
and (CGX8)5 constructs. These results mirror our previous findings

56

and also match sequence

based nucleosome occupancy predictions using a web-based tool 79. This consistency potentially
suggest that the nucleosome occupancy map can be partially determined by the TA, TT, AA and
GC dinucleotide phasing as revealed in previous literature 79.
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Closed Conformation

Open Conformation

Figure 2.4.2: Energy transfer efficiencies of reconstituted mono-nucleosomes at [KCl]= 100mM.
The inset illustrates the labelling position of the FRET pair and the two possible nucleosomal
conformations, closed and open conformation. Data = mean ± standard error (n>3) and *: p value
< 0.0001, #: p value <0.001

Increasing salt concentration from 10 to 100 mM slightly increases E by <10 %, suggesting
that a more compact conformation is being adopted, which can be attributed to the neutralization
of surface charges of DNA by K+ cations. The effects of both 5mC and 5hmC, interestingly, exhibit
significant dependence on the DNA sequence context. Specifically, methylation of all cytosines
leads to a decrease in E values for the Widom-601 sequence (p<0.0001), Fig. 2.4.2. The 5mC
DNA constructs with additional (CG)5 did not have significantly different E values from the
unmodified controls. However, a pronounced increase in E was observed in nucleosomes
containing the additional (CGX8)5, suggesting a more compact conformation due to cytosine
methylation (p<0.001). 5hmC lead to a decrease in the E value for the Widom 601 sequence
(p<0.0002), while causing a significant increase in the energy transfer efficiency for the (CG)5
construct (p<0.0001). Almost no change in E was seen for the (CGX8)5 construct due to
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hydroxymethylation. Relative changes in E values caused by 5mC and 5hmC are plotted in Fig.
2.8.6(A) and (B).
The relative change in E values (wherever significant difference was observed) translates
to a distance change of ~ 0.2-0.4 nm (estimated using R0 = 5 nm). The distance change suggests
that around 2-4 bp of DNA (0.34 nm/bp) at the nucleosome entry/exit sites can be affected by the
DNA sequences and modifications. Since the methylation and hydroxymethylation levels that we
introduced to DNA are much higher than what typically occurs in living cells, we do not expect
DNA modifications to significantly alter the static conformation of chromatin in vivo. The changes
in dynamic features, e.g., changes in DNA end breathing motions induced by hydroxymethylation,
may have an effect on the initiation of transcription events, such as when a transcription factor or
a remodelling factor is trying to access a specific DNA sequence. Overall, 5mC and 5hmC can
affect the DNA end breathing motion in a certain sequence context.
2.4.3 DNA methylation and hydroxymethylation reduce nucleosomal stability
The nucleosome stability partially encodes for the accessibility of DNA to various nuclear
proteins and may determine the transcription state of chromatin68,80. DNA epigenetic modifications
and histone post-translational modifications are both known to contribute to the stability of
nucleosomes56,81

71,73,82

. We measured the E values of labelled mono-nucleosomes at increasing

salt concentrations (0-1200 mM KCl), with typical results shown in Fig. 2.8.7.

The salt

concentration at which half the FRET signal was lost (termed as C50) was used to characterize the
stability of mono-nucleosomes. Lower C50 values suggest a less stable nucleosome and similar
approaches have been widely adopted to monitor nucleosome stability and dissociation pathways
in literature56,71,72. Nucleosome stability does not vary significantly for the three different sequence
constructs in the unmodified state, as seen in Fig. 2.4.3(A). The most pronounced changes in the
C50 values arise from the addition of methyl and hydroxymethyl cytosines. Independent of the
sequence context, these modifications decrease the C50 value and thus the stability of nucleosomes
(p< 0.001). The relative change induced by both modifications, calculated as (C50,(5mC/5hmC)C50,control)/C50,control, where C50,(5mC/5hmC) and C50,control is the C50 value of nucleosomes containing
5mC or 5hmC and unmodified control, respectively were not significantly different from each
other, as seen in Fig. 2.4.3(B) (tested with p=0.5).

16
(A)

(B)

Figure 2.4.3: (A) A summary of C50 values of all DNA constructs with different DNA
modifications. (B) The relative changes in C50 values due to cytosine modifications. There is no
significant difference between the effects of 5mC and 5hmC as compared to the unmodified
constructs (n>3). These values were obtained from the results of three (or more) independent sets
of reconstitutions for all three constructs.

However, given the enhanced affinity of 5hmC DNA for the histone octamer, the reduced
stability values of the 5hmC nucleosome (as compared to the unmodified sequence) was a
surprising finding. We resolved this apparent contradiction by examining the affinity of 5hmC to
H2A-H2B dimers. An alternative labelling strategy (DNA end (acceptor) and histone octamer
(donor located at H4) was also used to examine the nucleosome dissociation process. Nucleosome
dissociation typically starts with dimer dissociation and ends with DNA peels off from H3-H4
tetramers. If 5hmC DNA has a reduced affinity for the dimer alone, the C50 values measured using
the alternative FRET strategy will be similar, while 5hmC should show lower affinities to H2AH2B dimers. This hypothesis was tested by competitive binding assays conducted using the
unmodified DNA, 5hmC DNA and the (H2A-H2B) dimer. The results are presented in Fig.
2.4.4(A) and Fig. 2.8.8(A). The ∆∆�2345 values of 5hmC DNA are higher when compared to the
unmodified sequence (p<0.0003), suggesting a reduced affinity for H2A-H2B dimers.
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(A)

(B)

Figure 2.4.4: (A) Graph showing the ∆∆�2345 values obtained from 4 independent reconstitutions
of unmodified DNA, 5hmC DNA, dimer or tetramer. (p < 0.0003 while comparing 5hmC and
unmodified Widom-601 for the dimer and p<0.05 for the tetramer). Control: Widom 601 DNA.
(B) The C50 values of unmodified or hydroxymethylated nucleosomes measured using the
alternative FRET labelling strategy. There is no significant difference between the 5hmC and the
unmodified DNA (n > 3, p < 0.6). These values were obtained from the results of three (or more)
independent sets of reconstitutions.

Using the alternative FRET labelling strategy, we examined the FRET signal between the
octamer surface and the DNA end over a salt gradient of 0-2 M KCl. By choosing this labelling
location, we were able to capture the nucleosomal dissociation dynamics governed by DNA and
histone tetramer interactions. The dissociation curves are presented in Fig. 2.8.9. We found that
C50 values were not statistically different between the unmodified and the 5hmC nucleosomes, as
shown in Fig. 2.4.4(B). These results were further supported by binding assays conducted using
(H3-H4) tetramers. Our results, as shown in Figs. 2.4.4(A) and 2.8.8(B), suggest that the ∆∆�2345
values were lower in case of the 5hmC DNA (p<0.05) compared with unmodified DNA. Overall,
our results confirmed that 5hmC as a modification reduces the affinity of the DNA for the histone
dimer (H2A-H2B). The same modification shows an increased affinity for the histone tetramer
(H3-H4).

18
Discussion
The nucleosome binding affinities, conformation and stability exhibit different dependence
on the DNA sequence and presence of DNA modifications. These variations are somewhat
expected since they reflect different dynamic features of nucleosomes. Specifically, the measured
nucleosome conformation is expected to be determined by the DNA end breathing motions. The
nucleosome stability monitored in our study has been proposed to primarily capture the dimer
destabilization process at modestly high salt concentrations71,72, while the binding affinities of
DNA to histone octamers include contributions from physical properties of the DNA sequence and
their interactions with positively charged histone octamer surfaces.
The nucleosome-binding affinity quantifies the likelihood of individual DNA sequences
being occupied by histone octamers68. The sequence dependence in the ∆∆�2345 values of
unmodified DNA sequences is likely to originate from various structural properties of individual
sequences (such as twisting and bending) as suggested in the literature67,83. Methylated DNA
shows reduced binding affinity for the histone octamers, similar to what has been observed in
previous literature 69,84 using DNA containing cytosine methylation within CG dinucleotides. This
reduction has been attributed to the hydrophobicity of the methyl group70. Interestingly, the more
hydrophilic 5hmC showed a trend opposite to 5mC by increasing the binding affinity of the DNA
for the tetramer. This finding suggests that the additional hydroxyl group in 5hmC would
compensate for the hydrophobicity of methyl group. Additionally, the hydroxyl groups may also
facilitate the nucleosome formation via additional hydrogen bonds.
The DNA end-breathing motion can contribute to the accessibility of nucleosomes to
transcription factors. This motion can be primarily attributed to the physical properties of DNA
fragments entering and exiting from nucleosomes. Methylated DNA exhibits higher rigidity85–87
and consequently leads to enhanced end breathing and a more open conformation in nucleosomes
as demonstrated in the Widom 601 and (CG)5 constructs. However, the methylation at (CGX8)5
position causes a compaction effect.
This location corresponds to additional cytosines in direct contact with the histone octamer.
Methyl side chain at this location would face away from the histone octamer and into the broadened
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major groove. These additional contacts between methylated cytosines and histone octamers seem
to help stabilize nucleosome conformations. Similar observations have been found in Genomewide association studies60, suggesting that methylated (CGX8)5 may impact DNA-histone octamer
interactions or DNA geometry.
Introduction of 5hmC to the Widom 601 (p<0.0002) and the (CG)5 (p<0.0001) constructs
leads to a more compact conformation as compared to the methylated counterparts. These effects
can be attributed to the increased flexibility imparted to the DNA by hydroxymethylation, which
has been reported previously

86

. The hydroxymethylated (CGX8)5 construct, however, shows

decreased E value compared to the methylated counterpart (p<0.001), implying an increased endto-end distance. This finding suggests that hydroxymethylated cytosines may interact with histone
octamers in a different way from methylated cytosines.
The nucleosome stability, as measured here for all three constructs using labels on the DNA
ends, accounts for the process of dimer destabilization and progressive unwrapping of DNA56,71,79.
Although it was expected that nucleosomes that form more readily should also demonstrate higher
stability during the dissociation experiment, our results were not in exact accordance to this
expectation. The C50 values obtained for both 5mC and 5hmC constructs show a decrease in
nucleosomal stability compared to the unmodified DNA.
Interestingly, our results for 5hmC show that while it increases the binding affinity of DNA
for the octamer, it also causes a decrease in stability of the formed nucleosomes. A similar
observation has been noted in a previous study comparing the stability and conformations of
nucleosomes containing 5S NPS and Widom-601sequences. This study suggests that the higher
ΔΔ Gnuc, but lower site exposure equilibrium of 5S NPS as compared to the 601 sequence arises
from the higher affinity of the 5S NPS to the H2A-H2B dimer than the 601 NPS

66,88

. The

discrepancy observed in our experiments can also be addressed by the fact that the stability
measurements were carried out using FRET pairs attached to nucleosomal DNA ends.
Consequently, C50 values as we obtained in this study will primarily reflect the dimer stability of
nucleosomes, i.e., the first step of nucleosome dissociation pathway as suggested in the recent
mechanical study of mono-nucleosomes71. Noting the results in

66,88

and combining it with the

20
dimer stability values obtained by ourselves, this contradiction can be explained by the fact that
5hmC DNA has a lower affinity for the H2A-H2B dimer, but a higher affinity for the H3-H4
tetramer. Hydroxymethylated DNA could thus be more transcriptionally accessible, consistent
with its proposed biological role as a demethylation intermediate to reverse transcriptional
silencing events39,48.
In conclusion, our findings show that hydroxymethylation of cytosines can have a
significant impact on nucleosomal properties. Hydroxymethylation leads to increased nucleosome
binding affinities and is more likely to be incorporated into nucleosomes. Once formed,
hydroxymethylated nucleosomes demonstrate dynamic nucleosome conformations depending on
the underlying DNA sequence contexts. Surprisingly, hydroxymethylated nucleosomes dissociate
at lower salt concentrations compared with unmodified nucleosomes, due to weaker contacts with
H2A-H2B dimers. Compared with methylation, hydroxymethylation plays an opposing role in
nucleosome assembly but demonstrates similar destabilization effect on assembled nucleosomes.
This property is consistent with the biological functionality of DNA hydroxymethylation. This
modification is abundant in regions such as TSS, promoters and exons of actively transcribed genes.
48,89

Our findings reveal the effects of 5hmC on nucleosomal properties, which has never been

studied before. It paves the way towards understanding how specific DNA modifications regulate
transcriptional dynamics in the context of CpG sites.
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Supporting Materials
2.8.1 Supporting table
Table 2.8.1 DNA sequences of three constructs used in this study. The underscored CG sites
indicate the additionally introduced CG sites at the central dyad (in Row 2) and the minor groove
(Row 3)
DNA

Sequence

Widom
601

ACTCCCTGGAGAATCCCGGTGCCGAGGCCG 13
CTCAATTGGTCGTAGACAGCTCTAGCACCG
CTTAAACGCACGTACGCGCTGTCCCCCGCG
TTTTAACCGCCAAGGGGATTACTCCCTAGT
CTCCAGGCACGTGTCAGATATATACATCCT
GTGCAGT
ACTCCCTGGAGAATCCCGGTGCCGAGGCCG 17
CTCAATTGGTCGTAGACAGCTCTAGCACCG
CTTAAACGCACGTACGCGCGCGCGCCCGCG
TTTTAACCGCCAAGGGGATTACTCCCTAGT
CTCCAGGCACGTGTCAGATATATACATCCT
GTGCGAT
ACTCCCTGGAGAATCCCGGTGCCGAGGCCG 19
CTCAATTGGTCGTAGACAGCTCTAGCACCG
CTTAAACGCACGTACGCGCTGTCCCCCGCG
TTTTCGCCGCCAAGCGGATTACTCCGTAGTC
TCCCGGCACGTGTCGGATATATACATCCTG
TGCGAT

(CpG)5

(CGX8)5

CpG Sites

Total
number
of C
51

51

53
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2.8.2 Supporting figures
Widom 601 sequence
ACTCCCTGGAGAATCCCGGTGCCGAGGCCGCTCAATTGGTCGTAGACAGCTCTAGC
ACCGCTTAAACGCACGTACGCGCTGTCCCCCGCGTTTTAACCGCCAAGGGGATTAC
TCCCTAGTCTCCAGGCACGTGTCAGATATATACATCCTGTGCAGT
(CG)5 sequence
ACTCCCTGGAGAATCCCGGTGCCGAGGCCGCTCAATTGGTCGTAGACAGCTCTAGC
ACCGCTTAAACGCACGTACGCGCGCGCGCCCGCGTTTTAACCGCCAAGGGGATTA
CTCCCTAGTCTCCAGGCACGTGTCAGATATATACATCCTGTGCAGT
(CGX8)5 sequence
ACTCCCTGGAGAATCCCGGTGCCGAGGCCGCTCAATTGGTCGTAGACAGCTCTAGC
ACCGCTTAAACGCACGTACGCGCTGTCCCCCGCGTTTTCGCCGCCAAGCGGATTAC
TCCGTAGTCTCCCGGCACGTGTCGGATATATACATCCTGTGCAGT
Figure 2.8.1: Sequence alignments of the three constructs used in this study. Original CG sites in
the Widom 601 sequence are in bold. Additionally introduced CG sites at the central dyad in the
(CG)5 construct and at the minor groove in the (CGX8)5 construct have been underlined and
italicized.
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(A)

(B)

Figure 2.8.2: Typical 6% polyacrylamide gel showing the (A) labeled and (B) unlabeled DNA
constructs (157bp) prepared by PCR.

Figure 2.8.3: Typical 5% polyacrylamide gel showing the reconstituted DNA and histone octamers.
All nucleosomes exhibit the same translational settings irrespective of the modifications present.
There is no unbound DNA in the system.
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Figure 2.8.4: Anisotropy values of the various combinations of DNA modifications and labels
show that the values are consistently below 0.25. This indicates that the dyes are freely rotating.

Figure 2.8.5: Energy transfer efficiencies of the reconstituted mono-nucleosomes at KCl=10mM.
The inset shows labeling position of the FRET pair and the two possible nucleosomal
conformations, closed and open. Data = meant ± standard error (n>3) and *: p value <0.0001, #: p
value< 0.001
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(A)

(B)

Figure 2.8.6: Relative changes in the energy transfer efficiency values due to (A) cytosine
methylation and (B) cytosine hydroxymethylation. Data = meant ± standard error (n>3).

Figure 2.8.7: Salt-dependence of energy transfer efficiency values for three DNA constructs,
where the (CGX8)5 modification shows an initial low value of E and a different slope as
compared to the other two constructs. These values were obtained from the data of three (or
more) independent sets of reconstitutions for all three constructs
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(A)

(B)

Figure 2.8.8: (A) Competitive binding of the Widom-601 unmodified, 5hmC and 5mC DNA
with the H2A-H2B dimer assayed on a 5% Polyacrylamide gel prior to EtBr staining. The
unlabeled competitor DNA used in this assay was the Widom-601 NPS at a concentration of 3
µM in the final reconstitution. The labeled DNA concentration was 0.04 µM and the dimer
concentration was 2.5 µM. The [dimer]: [DNA] was 0.85. Three different sets of reconstitutions
were carried out for each of the DNA (B) Competitive binding assays of the same three DNA
with the (H3-H4) tetramer. The reaction conditions are identical to the dimer case
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(A)

(B)

(C)

Figure 2.8.9: Competitive binding of the (A) (CG)5 and (B) (CGX8)5 unmodified and 5hmC
DNA with the H2A-H2B dimer assayed on a 5% Polyacrylamide gel prior to EtBr staining. The
unlabeled competitor DNA used in this assay was the Widom-601 NPS at a concentration of 3
µM in the final reconstitution. The labeled DNA concentration was 0.04 µM and the dimer
concentration was 2.5 µM. The [dimer]: [DNA] was 0.85. Two different sets of reconstitutions
were carried out for each construct. (C) Graph showing the ∆∆�2N values obtained from 2
independent reconstitutions (p<0.05 while comparing 5hmC and control samples). Control:
Widom 601 DNA.
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Figure 2.8.10: Energy transfer efficiency curves of the Widom-601 and 5hmC DNA
reconstituted with a FAM labeled octamer. The two FRET labels used are a TAMRA label on
the DNA end and a FAM label on the H4 of the octamer (the serine 47 of H4 was modified to
cysteine and labeled with a site-specific FAM label). The salt concentration was varied from 0-2
M KCl, at the end of which complete dissociation is expected.
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3. CPG DINUCLEOTIDE POSITIONING PATTERNS DETERMINE THE
BINDING AFFINITY OF METHYL-BINDING DOMAIN TO
NUCLEOSOMES

This chapter consists of a manuscript by Mendonca A, Sanchez O, Liu W, Li Z and Yuan C that
was published in BBA-Gene Regulatory Mechanisms, 1860 (2017), 713-720.

Abstract
The methyl-binding domain of MBD1 is a common methyl CpG binding motif and has been linked
to transcriptional repression. Understanding the dynamics of MBD1 binding to nucleosomal DNA
is crucial, but the molecular interactions between MBD1 and chromatin remain elusive. In this
study, we found the binding of MBD1 to nucleosomes demonstrates sequence preferences
depending on the position of the methyl groups on the nucleosome. Specifically, binding was
favored at

me

CpG sites in the dyad proximal region and facing towards the histone octamers. At

locations where the

me

CpG sites face away from the histone octamer, the binding affinity was

significantly lower. Interestingly, the binding of ΔMBD1 at methylated CpG sites facing away
from histone octamers induces conformational changes of nucleosomes, resulting in a more “open”
conformation. The biological implication of DNA methylation is thus likely to be synergistically
regulated via DNA sequences contents and their nucleosome-positioning patterns based on our in
vitro findings.

Introduction
Methylation of DNA at the C5 position of cytosine in a CpG dinucleotide is an important
epigenetic modification90,91. DNA methylation regulates a number of important genetic processes
such as X-chromosome inactivation 92, gene imprinting 93 and heterochromatin formation94. DNA
methylation is primarily associated with transcriptional silencing37,95,96. The prevailing mechanism
suggests that a methylation-affiliated repressive transcriptional state can be initiated and
maintained by the binding of methylation-specific proteins, e.g., MeCP2 and MBD197. In
mammals, the methyl binding domain (MBD) family of proteins selectively bind to methylated
cytosine, within a CpG (meCpG) dinucleotide in particular90,98. The MBD family consists of
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proteins such as MBD1, MBD2, MBD3, MBD4 and MeCP2. Among these, MBD1, MBD2,
MBD3 and MeCP2 are known transcriptional repressors 99,100, while MBD4 is primarily involved
in DNA mismatch repair101. Understanding the molecular interactions of these methyl-binding
proteins with chromatin can help providing a holistic picture revealing their roles in gene
regulation.
MBD1 is the most abundant of the MBD proteins102 and is present at a protein-to-DNA
ratio of around 1: 1670 in cells 103. It acts as a transcriptional repressor by binding to chromatinmodifying complexes, such as MCAF 104 and Suv39h1-HP1 heterochromatic complex 105, which
then facilitate the formation of heterochromatin. The MBD family contains a conserved methylbinding domain 98 which is responsible for recognizing meCpG. The full length MBD1 protein has
a transcriptional repressor domain (TRD)106 and CXXC domains (e.g., CXXC-3 binds to
unmethylated DNA with no sequence specificity and is speculated to primarily assist in
transcriptional repression via steric hindrance107). The specificity for methylated DNA is conferred
primarily by the methyl binding domain of MBD1 which also ensures its binding stability to target
genes103,108. We thus primarily focused on the methyl-binding domain of MBD1 in this study. The
Methyl-binding domain of MBD1 can readily form a complex with methylated DNA 109 and has a
Kd value of ~30 µM for a single meCpG site 110,111. The structure of MBD1-DNA complex suggests
that the methyl-binding domain of MBD1 primarily interacts with DNA in the major groove109.
Similar observations have been made using other types of methyl-binding domains 112.
In eukaryotic cells, genomic DNA does not exist as an independent entity. Instead, it is
complexed with histone proteins forming nucleosomes, and is thus condensed into chromatin. The
formation of nucleosome renders a transcriptional barrier that occludes DNA from accessing many
protein factors113. The implication of high-order chromatin structure on the binding of methylbinding domains is poorly understood. Early studies using MeCP2 have shown that MeCP2
interacts with nucleosomes and forms a complex retaining core histone proteins 114,115. Methylated
CpG sites show a distinct distribution in the genome. Recent genome-wide-association-studies
(GWAS) have revealed that meCpG sites exist predominantly at 10 bp periodicity with meCpG sites
in direct contacts with histone octamers116. The implication and cause of this pattern remains
elusive. Understanding how methyl-binding domains interact with meCpG at different nucleosomal
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locations can thus contribute to unravel the molecular mechanism of establishment and
maintenance of DNA methylation patterns in the genome and potentially shed light on the
formation mechanism of methylation-induced heterochromatin.
In this study, we examined the binding of the methyl binding domain of MBD1 (henceforth
referred to as ΔMBD1) to nucleosomes, in the context of biologically relevant methylation patterns.
We found that ΔMBD1 can form stable complexes with nucleosomes containing methylated DNA.
We selectively introduced

me

CpG sites at different nucleosomal locations based on the

nucleosomal DNA coordinate. Our results suggest that ΔMBD1 preferentially binds to CpG sites
located in the central dyad and at 10 bp intervals with CpG sites facing towards the histone octamer
(in direct contact). The binding of ΔMBD1 to meCpG sites in the nucleosomal DNA facing away
from the histone octamer is less favored; and the complex formation is associated with a significant
conformational change of nucleosome. The binding of ΔMBD1 to nucleosomes showed positive
cooperativity in some of the examined constructs. Our in vitro findings reveal the distinctive
binding behaviors of ΔMBD1 at various nucleosomal locations.

Materials and Methods
3.3.1 Preparation of fluorescently labeled nucleosomes
Four types of DNA constructs with different CpG patterns were used in this study. The
detailed DNA sequences are included in Table 3.3.1. The sequences of these DNA fragments were
derived from the Widom-601 sequence (henceforth referred to as Control nucleosome or Control),
which has one of the highest known binding affinities to histone octamers 62. As the DNA wraps
around the nucleosome, it has contact points with histone octamer at ~ 10 bp intervals53,64. Similar
to our previous study

56

and based on the crystal structure of the 601 nucleosome

117,118

, we

selectively introduced CpG sites at three distinctive nucleosomal locations, namely (i) an
additional (CG)5 stretch in the region adjacent to the central dyad (a pattern of (CG)5); (ii) five
CpG dinucleotide repeats at 10bp intervals where the additional CpG sites face away from histone
octamer ((CGX8)5,away); and (iii) five CpG dinucleotide repeats at 10bp intervals where the
additional CpG sites face towards and are in direct contact with the histone octamer ((CGX8)5,towards)
as shown in Table 3.3.1.
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Table 3.3.1: Table showing the 157 bp DNA constructs used in this study. Control is the original
Widom-601 sequence, while (CG)5, (CGX8)5,away and (CGX8)5,towards constructs contain
additional CpG sites by design. The numbers above the sequences correlate to the distance from
the dyad; ‘-’ and ‘+’ signs indicate the negative and positive directions from the dyad (at 0). The
sequence from -78 to the dyad (0) is the same for all four constructs. Sequence changes
introduced in the dyad (0) to +78 region are underscored in red and in bold text. Highlighted in
bold and blue are the original meCpG sites in the control DNA sequence. The 6 bp linkers added
to the original 145 bp Widom 601 nucleosome are highlighted in grey.

Two types of DNA samples, methylated and unmethylated were prepared as described
previously 56. Briefly, the bacterial methyltransferase, M.SssI (New England Biolabs) was used to
transfer a methyl group to the cytosine in a CpG dinucleotide context, from the methyl donor Sadenosylmethionine (SAM). The extent of methylation was verified by methylation-sensitive
restriction enzyme digestion as shown in Fig. 3.10.1(A).
Fluorescent labels were introduced to the DNA ends using fluorescently labeled primers.
For each DNA sample, we prepared three types of labeled DNA, namely (1) a donor-only sample
tagged with fluorescein (FAM, donor); (2) a dual-labeled sample tagged with FAM (donor) and
tetramethylrhodamine (TAMRA, acceptor); and (3) an acceptor-only sample tagged with TAMRA.
The prepared DNA samples were analyzed using a 6% polyacrylamide gel (Fig. 3.10.1(B)) and
were purified using the same approach as we described previously 65. The labeling efficiencies of
the samples were calculated following an established approach 65. The FAM and TAMRA labeling
efficiencies were consistently observed to be > 90% across all the constructs.
Experimentally, mono-nucleosomes were reconstituted by mixing DNA with refolded
recombinant histone octamers at an optimized stoichiometric ratio as described before 65. Linker
histone H1 was not included in the reconstitution process; only the core histones H2A, H2B, H3
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and H4 were used. Nucleosomes reconstituted using methylated DNA are henceforth referred to
as “methylated nucleosomes”. Similarly, the unmethylated DNA-octamer complex is referred to
as “unmethylated nucleosomes”.
The reconstituted mono-nucleosome samples were examined using a 5% polyacrylamide
gel as shown in Fig. 3.10.2. The resolution of the 5% polyacrylamide gel was further verified using
nucleosomes containing various defined linker lengths, namely 0-N-12 (where N is the original
145 bp Widom-601 sequence) and 1-N-1, in comparison with our reconstituted control nucleosome,
which is expected to assume a 6-N-6 configuration. As shown in Fig. 3.10.3, the 5% gel can easily
resolve 5 bp changes in translational settings. We thus expect all samples to exhibit a single
translational setting with no detectable free DNA fragments. To further validate the first point and
gain insights about the rotational setting of the reconstituted nucleosomes, we predicted
nucleosome positioning pattern using an established computation tool 79 and performed nuclease
digestion assays (DNase I hypersensitivity assay) following an established protocol119. The
predicted positioning pattern is depicted in Fig. 3.10.4, suggesting homogeneous translational
settings consistent with our previous findings. DNAse I hypersensitivity assay (Fig. 3.10.5) shows
uniform digestion pattern suggesting similar rotational settings among all constructs.
3.3.2 Preparation of ΔMBD1
The amino acid sequence of wild-type ΔMBD1 is shown in Table 3.3.2. The coding
fragment of ΔMBD1 was subcloned into a pET21b vector and expressed using E. coli cultures as
described previously120. ΔMBD1 (molecular weight of 9.6 kDa) was primarily expressed as
inclusion bodies, purified using Nickel-agarose beads and was refolded following our established
protocol120.

Table 3.3.2: Amino acid sequence of wild-type ΔMBD1.
Protein
Wild-type
ΔMBD1
(88 aa)

Amino acid sequence
10

20

30

40

50

60

MAEDWLDCPA LGPGWKRREV FRKSGATCGR SDTYYQSPTG DRIRSKVELT RYLGPACDLT
70

80

LFDFKQGILG GGGTGGGGSL EHHHHHHH
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3.3.3 Characterization of ΔMBD1 binding to nucleosomes of varying meCpG patterns
The binding of ΔMBD1 to nucleosomes was evaluated by mixing ΔMBD1 with
nucleosomes (fixed at 0.4 µM) at different molar ratios ([ΔMBD1] : [Nuc] = 0 - 70). The binding
reaction was performed in a buffer containing 100 mM KCl, 10 mM Tris-HCl pH 7.9, 1 mM EDTA
and 1 mM DTT resembling physiological ionic strength. The mixture was incubated for ~ 30
minutes at room temperature prior to analyzing on a 5% native polyacrylamide gel. Typical gels
showing the electrophoretic mobility shift assay (EMSA) results are included in Fig. 3.4.1(A).
Upon binding, nucleosomes show an upward shift of mobility due to increased complex size.
ImageJ (NIH, Bethesda, MD) was used to quantify the intensity of individual bands. Specifically,
we determined the percentage of unbound nucleosomes by quantifying the intensity of the unbound
nucleosome band relative to the total sample loaded in each well. The EMSA sensitively quantifies
the relative amount of nucleosome-ΔMBD1 complex at high [ΔMBD1] to nucleosome ratios. In
order to validate the findings obtained by EMSA, we employed another method to calculate the
fraction of bound nucleosomes by using FCS, as described in the supplementary materials (see
Supporting Methods and Fig. 3.10.6). ΔMBD1 with a fluorescent label (fluorescein) was
prepared for the FCS assay, as described in Table 3.10.1 and Supporting Methods. The findings
at different [ΔMBD1] : [Nuc] were compared to EMSA results and found to be similar to each
other , as shown in Fig. 3.10.7, suggesting that these two approaches generate consistent binding
data.
We used the Hill equation121 to determine the dissociation constant and the binding
cooperativity of ΔMBD1. Hill equation (Eq.1) is typically used to analyze multiple ligand binding
processes122,123. Experimental results were fitted using Eq.1.
�=

[∆QRKS]U
[∆QRKS]U V(<- )U

Eq.1

where, Kd is the macroscopic binding constant, � is the fractional occupancy of the nucleosomal
sites, [ΔMBD1] is the concentration of free ΔMBD1, h is the Hill coefficient (indicating
cooperativity of binding). Experimentally, � was calculated as show in Eq. 2
� = 1−

H=
HW

Eq.2

where, Ni is the band intensity of unbound nucleosomes at a given [ΔMBD1] to [Nuc] ratio; and
NO is the band intensity of total nucleosomes without any ΔMBD1 added.
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3.3.4 Characterization of nucleosome conformation using FRET
Förster Resonance Energy Transfer (FRET) was used to study the conformational change
of nucleosomes by monitoring the end-to-end distance of nucleosomal DNA. The FRET efficiency
was calculated using fluorescence lifetime collected via a time-domain fluorescence lifetime
spectrophotometer. The detailed experimental setting has been described in our previous work 124.
Higher values of energy transfer efficiency (E) correspond to smaller end-to-end distance of
nucleosomal DNA, and thus suggest a more compact nucleosomal conformation. Lower E value
is expected to correlate to a more “open” nucleosome conformation.
Anisotropy of fluorescently labeled nucleosomes (FAM- or TAMRA- tagged) was
measured using a SpectraMax M5 Microplate Reader (Molecular Devices). The collective
anisotropy values at varying [ΔMBD1]:[Nuc] ratios are shown in Fig. 3.10.8. The anisotropy
values of all dyes were found to be consistently below 0.3 and are independent of ΔMBD1
concentrations. The attached fluorescent dyes can thus be considered freely rotating. The observed
changes in energy transfer efficiencies can be attributed primarily to the distance change between
FRET pairs125.

Results
3.4.1 ΔMBD1 binds to unmethylated and methylated nucleosomes with differing affinity.
We evaluated the binding of ΔMBD1 to reconstituted mono-nucleosomes with different
methylation levels using EMSA (as described in the methods section (characterization of ΔMBD1
binding to nucleosomes). A typical gel image is shown in Fig. 3.4.1(A). We observed a distinct
preference of ΔMBD1 to methylated nucleosomes (e.g., methylated Control). Similar preference
for methylated nucleosomes was also observed for the other three constructs (see Fig. 3.4.2(A)
and Fig. 3.10.9). Consistently, at similar [ΔMBD1]:[Nuc] ratios, nucleosomes containing
methylated DNA migrates with lower electrophoretic mobility suggesting the formation of
ΔMBD1-nucleosome complex.
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(A)

(B)

Figure 3.4.1: (A) Binding pattern of ΔMBD1 to nucleosomes with varying methylation levels (0
and 100%) as seen by the relatively slower migration of the ΔMBD1-Nucleosome complex.
Nucleosomes with the control DNA sequence were used in this gel. Samples were assayed on a
5% Polyacrylamide gel. (B) Gel slices were excised as indicated in (A) and run on an 18% SDSPAGE gel. Slices were selected to include the prominently bound complex as well as some
excessive parts (i.e., upper and lower smearing for cutting slice 1 and 2, respectively) to capture
any possible ΔMBD1-nucleosome complexes. The unmethylated sample (Slice 1) does not have
any ΔMBD1 while the methylated samples (Slice 2) show the co-localization of ΔMBD1and
histones H2A-H2B. The last two lanes are protein markers containing ΔMBD1 and refolded
histone octamers, respectively.

To facilitate the interpretation of EMSA, we analyzed the content of gel bands by excising
them from a native gel. Specifically, we excised the two bands, indicated by boxes in Fig. 3.4.1(A).
Excised samples were analyzed using an 18% SDS-PAGE and stained by Coomassie Blue as
shown in Fig. 3.4.1(B). Slice 1, corresponding to unmethylated nucleosomes, primarily consists
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of core histone proteins. No ΔMBD1 band can be visually detected. The high bands obtained from
methylated nucleosome samples clearly show the presence of both ΔMBD1 and histone proteins.
However, since the ΔMBD1 and the histone H4 have similar molecular weights (9.6 and 11 kDa,
respectively), we further verified the identity of the proteins via Western blotting as shown in (Fig.
3.10.10). Antibodies specific for Histone H4 (Active Motif, Carslbad, CA) and the 6 × C-terminal
His tag on the ΔMBD1 protein (Life Technologies, Grand Island, NY) were used and confirmed
the protein identity as expected. Our results thus suggest that ΔMBD1 preferentially binds to
nucleosomes containing methylated DNA. Histone proteins also seem to be retained in the
complex afterΔMBD1 binding.
3.4.2 ΔMBD1-binding depends on CpG methylation pattern.
We introduced defined CpG methylation patterns to DNA guided by the coordinates of
nucleosomal DNA56,116. Table 3.3.1 illustrates the defined CpG methylation patterns. The binding
of ΔMBD1 to nucleosomes with varying meCpG patterns were examined using EMSA and verified
by FCS assays. Our results are summarized in Figs. 3.4.2(A) and (B). The binding curve of each
construct was also individually depicted in Fig. 3.10.11.
Fig. 3.4.2(A) summarizes typical binding patterns of ΔMBD1 to four types of methylated
(100%) nucleosomes. The binding pattern of ΔMBD1 differs based on the introduced

me

CpG

patterns. This trend was absent in similar assays carried out using naked DNA (Fig. 3.10.12, where
ΔMBD1 exhibits similar binding behaviors independent of

me

CpG patterns. The binding affinity

of ΔMBD1 is apparently lower for methylated nucleosomal DNA than naked DNA.

This

difference is pronounced when comparing the binding fraction at [ΔMBD1] : [Nuc] = 5 as shown
in Fig. 3.4.2(A) and Fig. 3.10.12. At this ratio, almost all naked DNA form complexes with
ΔMBD1, while nucleosomal DNA are just partially bound to ΔMBD1. The distinctive binding
behavior of ΔMBD1 to nucleosomes, as observed in Fig. 3.4.2(A) is thus likely to be attributed to
me

CpG accessibility regulated by the formation of nucleosomes instead of varying sequence

contents alone.
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(A)

(B)

Figure 3.4.2: (A) Typical EMSA results of ΔMBD1 and nucleosome binding. Samples were
analyzed on a 5% Polyacrylamide gel and run at 200 V for 3 hours. (B) The fraction of bound
nucleosomes (θ, calculated as described in Eq. 2) was plotted against concentration of un-bound
(free) ΔMBD1. Binding curves were fitted using the Hill equation (Eq.1). Dashed lines represent
the fitted Hill curves for each construct. The error bars represent standard deviations and are
small enough to be indiscernible for some of the points. Fitting parameters are summarized in
Table. 3.4.1. Data = mean ± standard deviations, n ≥ 3.

We estimated the apparent dissociation constants (Kd) using Eq.1. The collective fittings
of binding results of each construct are summarized in Fig. 3.4.2(B) and Table 3.4.1. The Hill
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equation was used to fit the binding data since it offered a significant fitting improvement over a
simple hyperbolic binding model (i.e., random residuals with R2 > 0.94 as compared to residuals
of a defined pattern with R2 < 0.85). The fitted Kd values reflect the averaged dissociation constants
while the Hill coefficient indicates cooperativity of binding. Hill coefficient values larger than 1
suggest the existence of positive cooperativity in binding. We found the largest Hill coefficient
for the (CG)5 construct and the largest Kd for (CGX8)5,away. To verify the robustness of fitting, we
selectively eliminated one point at high [ΔMBD1] where inaccuracy in measurements is most
likely to occur and repeated our fitting for both dataset. Our results for both constructs are shown
in Table 3.10.2 and Fig. 3.10.13 yielding very similar fitting results.

Table 3.4.1: A summary of Kd, Hill coeffecient values and R2 fitted using our binding results.
Four nucleosomes containing different CpG patterns were both 100% methylated.
Construct
Control
(CG)5
(CGX8)5,away
(CGX8)5,towards

Kd (µM)
1.5 ± 0.2
1.1 ± 0.2
2.8 ± 0.2
1.0 ± 0.1

Hill coeffecient
1.0 ± 0.1
4.2 ± 0.2
0.9 ± 0.1
1.5 ± 0.2

R2 of fitting
0.97
0.95
0.97
0.94

Among all constructs, ΔMBD1 demonstrated the highest binding affinity for methylated
CpG sites in the central dyad proximal region ((CG)5) and facing towards the nucleosome
((CGX8)5,towards). The Kd values of (CG)5 and (CGX8)5,towards constructs are statistically
lower than the control (p < 0.01, Tukey HSD test), suggesting higher affinity. (CGX8)5,away
nucleosome exhibited the highest Kd value and hence the lowest affinity for binding. All constructs
had variable Hill coefficients either larger than or close to one, indicating either positive or no
cooperativity respectively in ΔMBD1 binding. The (CG)5 construct exhibits the largest degree of
positive cooperativity, while the (CGX8)5,towards construct exhibits some degree of positive
cooperativity in binding. To further validate our findings, additional binding assays were
performed using nucleosomes of lower concentrations as shown in Fig. S14 (Supplementary
Information).

Using 0.1 µM of nucleosomes, the Kd value and Hill coefficient for the

(CGX8)5,away were found to be 2.8 ± 0.1 and 1.2 ± 0.1, respectively. The Kd value and Hill
coefficient for the (CG)5 construct were found to be 0.8 ± 0.2 and 3.7 ± 0.3. ΔMBD1-binding can
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perturb nucleosomal conformation. We further explored the structural changes of nucleosomes
associated with ΔMBD1 binding. The dynamic conformation of nucleosomes can be assessed by
quantifying the end-to-end distance of nucleosomal DNA as we showed previously56. The FRET
label was introduced to the terminal ends of nucleosomal DNA. Lower E values are thus associated
with longer distance between FRET pairs and changes in DNA-histone octamer contacts. The
average E values and changes in end-to-end distance of nucleosomal DNA of different nucleosome
constructs are summarized in Fig. 3.10.15 and Fig. 3.4.3, respectively.

Figure 3.4.3: Average change in end-to-end distance between DNA ends over a range of
concentrations of [ΔMBD1]:[Nuc] compared to [ΔMBD1]:[Nuc] =0 . The x-axis represents the
range of [ΔMBD1]:[Nucleosome] over which the distance change was calculated. The * symbol
indicates that the observed change is statistically significant (p<0.001) using the Tukey HSD test.
Data = mean ± standard deviations, n ≥ 3 independent reconstitutions. The dotted line represents
the threshold above which statistically significant distance change was observed.
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Among all four constructs, the end-to-end distance of nucleosomal DNA remains fairly
constant for the Control nucleosome under different ΔMBD1 concentrations. Although ΔMBD1
can bind to the Control nucleosome at the examined [ΔMBD1]:[Nuc] ratio (see Figs. 1(A) and
2(A)), the formation of the ΔMBD1-nucleosome complex does not result in any significant
conformational change. The other three constructs, namely (CG)5 at central dyad adjacent location,
(CGX8)5,towards and (CGX8)5,away, all exhibit a significant distance change as ΔMBD1
concentration increases. At [ΔMBD1]:[Nuc] = 5, the distance changes are insignificant and can be
potentially attributed to fluctuations, e.g., caused by DNA end breathing motion or H2A-H2B
dimer dissociation. When the ratio was increased to 30, when multiple ΔMBD1 are expected to
bind to a single nucleosome, significant changes in the end-to-end distance were observed for the
(CGX8)5,away and (CGX8)5,towards constructs. At an even higher ratio, changes persist and
increase in these two constructs, while a small distance change was observed for the (CG)5
construct. Over the entire range of the binding ratios, the most dramatic changes in distances were
observed for the (CGX8)5,away. Contrastingly, this is also the construct that has the lowest affinity
for ΔMBD1. At [ΔMBD1]: [Nuc] = 70, the observed distance change for (CGX8)5,away construct
is equivalent to ~ 4-5 DNA base pairs being peeled away from histone octamers at each side,
assuming the nucleosome conformational change was primarily driven by DNA peeling away from
histone octamer surface.

The conformational change associated with the (CGX8)5,towards

constructs at an equivalent [ΔMBD1]:[Nuc] ratio corresponds to less than half of this value (2 bp).
Nucleosomes with the

me

CpG patterns adjacent to central dyad (me(CG)5) exhibit even less

pronounced changes.

Discussion
3.5.1 ΔMBD1 binds preferentially to methylated nucleosomes forming stable complexes.
The full-size MBD1 protein with both CXXC and MBD domains can bind to either
methylated or unmethylated DNA107. The MBD domain (ΔMBD1) alone selectively binds to
me

CpG in DNA form107,126. The crystal structure of ΔMBD1 bound to methylated DNA shows that

the ΔMBD1 binds DNA exclusively in the major groove127, with a small interfacial area. A protein
docking model has been established suggesting that the ΔMBD1 can preferentially bind to the
nucleosomal DNA when it is methylated, minimally disrupting the original histone-DNA contacts
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127

. There is, however, no direct experimental evidence characterizing the binding of ΔMBD1 to

nucleosomes.
To the best of our knowledge, we were able to characterize for the first time that ΔMBD1
binds selectivity to

me

CpG in nucleosomal DNA. There is a distinct binding preference for

methylated nucleosomes over unmethylated nucleosomes in our in vitro binding assays.
Interestingly, the binding of ΔMBD1 to nucleosomes exhibits positive cooperativity for two of the
constructs, suggesting that the binding of one ΔMBD1 is likely to facilitate the binding of one or
more subsequent ΔMBD1 domains. Combined with our conformational study (FRET results in
Fig. 3.4.3), it seems to suggest that ΔMBD1 can perturb the original conformation of the
nucleosomal DNA depending on the meCpG pattern.
3.5.2 ΔMBD1 binding is dependent on meCpG pattern.
Variations in the binding affinity of ΔMBD1 to the four constructs were noted in a CpGpattern-dependent manner. We observed a preference for ΔMBD1 binding to

me

CpG near the

central dyad and to the (CGX8)5,towards construct. The preference for the region adjacent to the
central dyad is consistent with what has been observed previously for the other methyl domain
binding proteins, i.e., MeCP2, which binds preferentially near the central dyad of nucleosomal
DNA128. The dyad proximal region was also found to be more accessible to other DNA-interacting
enzymes, e.g., glycolsylases of the base excision repair pathway and transcription factors66,129.
The central dyad proximal region only has a single DNA turn and thus presents less steric
hindrance for the binding of protein factors. This nucleosomal conformation can thus contribute
to the observed high affinity between ΔMBD1 and meCpG adjacent to the central dyad.
The

me

CpG pattern that showed the highest Kd value and thus lowest affinity was the

(CGX8)5,away construct. CpG sites at this location point away from the histone octamer surface.
Methyl groups at these sites would, however, are in close contact with the histone octamer (see
Fig. 3.5.1(A)). These contacts prevent the access of meCpG to the ΔMBD1 and result in decreased
binding affinity of ΔMBD1 consistent with our experimental observation. Moreover, the binding
of ΔMBD1 to this type of nucleosome is affiliated with the largest disruption of nucleosomal
conformation (see Fig. 3.4.3) suggesting that the nucleosomal DNA may need to change its
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orientation, rotational settings most likely, to be accessible to ΔMBD1. meCpG sites at nucleosomal
locations facing away from the histone octamer are thus not easily accessible for either methylation
reading or editing. The GWAS in literature suggests that these locations are light in DNA
methylation116. It is likely that since the meCpG at these locations are not easily accessible to their
epigenetic “reader” domains, their presence is barely recognized and may not play a significant
role in chromatin regulation.
In the (CGX8)5,towards construct, the added CpG sites are in direct contact with the histone
octamer at minor groove(see Fig. 3.5.1(B)). The methyl groups thus face outwards and away from
the octamer surface as shown in Fig. 3.5.1(B). These methyl groups would then be preferentially
positioned for binding to the ΔMBD1. Although intuitively we may expect that these CpG sites to
be less accessible because of the histone-DNA contacts, the binding of ΔMBD1 does not seem to
require very significant disruption of the original histone-DNA contacts as evidenced by our FRET
study (see 0-5 and 0-30 range in Fig.3.4.3). The outward-facing methyl-group is sufficient for the
binding of ΔMBD1. This construct is thus expected to have a low Kd value based on the structure
of nucleosomal DNA consistent with our experimental finding. Interestingly, this meCpG pattern
is also reported as the dominant positioning pattern of meCpG in GWAS116.
Based on our experimental findings, ΔMBD1 has a substrate preference in the order of
(naked DNA) >> (CG)5 ≈ (CGX8)5,towards > (CGX8)5,away. We examined the possibility that this
binding preference may originate from the presence of specific DNA sequences as preferential
targets for ΔMBD1. It has been shown that ΔMBD1 has higher affinity for the TmeCGCA and
TGmeCGCA sequence103, both of which were absent in all four constructs. In contrast, the least
efficient sequence for recognition (CmeCGGC) is present in the (CGX8)5,towards construct alone.
Despite the presence of this sequence, the (CGX8)5,towards construct demonstrates the highest
affinity to ΔMBD1.
It is thus possible that without the presence of (CmeCGGC), the Kd value of (CGX8)5,towards
might be even lower than the current observation (~1 µM). Since the number of CG sites differs
among the constructs, we also determined any potential correlation between the number of CpG
sites and the Kd value. A correlation analysis yields a Pearson’s correlation coefficient of 0.14,
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suggesting there are no significant correlations between these two factors. The difference in
binding behaviour among varying nucleosome constructs are thus likely to be attributed to the
distinctive locations where the added CpG sites were introduced.

(A) (CGX8)5,away

(B) (CGX8)5,towards

Figure 3.5.1 Schematic illustrations of the positioning of the methyl groups in the (A)
(CGX8)5,away and (B) (CGX8)5,towards constructs. Only DNA sequence from 0 – 72 was plotted for
the clear illustration of methyl-group locations. The structure was adapted from the crystal
structure of nucleosome core particle composed of the Widom 601 DNA sequence (PDB: 3LZ0).

The maximum fold difference in Kd values in this study is ~3 fold (between (CGX8)5,towards
> (CGX8)5,away constructs). Previous GWAS studies have shown that nucleosomal DNA
predominantly exhibits a 10 bp periodicity in the occurrence of CpG dinucleotides

116

. It is thus

interesting to understand the difference between these two patterns, both of which occur at a 10 bp
periodicity. The affinity difference is arguably modest. They are, however, sufficient to give rise
to target-specificity in ligand recognition in many biological systems. For instance, the UHRF2SRA domain has binding specificity for 5-hydroxymethylated DNA (5hmC) as compared to hemihydroxymethylated and unmodified cytosines130, even though the fold difference in the binding
affinities is found to be 2 and 3, respectively. Similar fold differences are observed in the affinity
of the methyl binding domain of MeCP2 which has a three-fold difference in Kd values for binding
to methylated C and hemi-methylated C131. The 3 fold difference in affinity between the

45
(CGX8)5,away and (CGX8)5,towards clearly suggests that the (CGX8)5,towards is a preferred substrate for
methylation recognition via ΔMBD1. This preference will determine how

me

CpG patterns are

recognized and utilized in epigenetic reading and editing.
3.5.3 ΔMBD1 binding can potentially perturb chromatin folding
We also observed that the binding of ΔMBD1 to nucleosomes was associated with varying
degrees of conformational changes, especially at high [ΔMBD1] : [Nuc] ratios. The most
significant changes in the average end-to-end distance of nucleosomal DNA were observed for the
(CGX8)5,away construct. Interestingly, this construct also has the lowest binding affinity to
ΔMBD1. In this construct, the additional meCG sites were placed in an orientation that prevents
easy access of methyl-side chains to ΔMBD1. The conformational perturbation in the
(CGX8)5,away is therefore likely to result from the changes in DNA rotational settings to make
the interior facing methyl sites more accessible. A significant but smaller distance change was also
noted for the (CGX8)5,towards construct. Although we do not expect the binding of ΔMBD1 at
these added CpG locations to induce significant disruptions of DNA-histone contacts, the
synergistic binding of ΔMBD1 at multiple meCpG locations (e.g., at high [ΔMBD1] : [Nuc] ratios),
especially at 10 bp periodicity, could perturb nucleosome folding as evidence by our experimental
observations. It is interesting to note that we see binding saturation at a ratio of [ΔMBD1]:[Nuc]=
30 for the (CG)5 construct based on our binding assay. Statistically significant changes in DNA
end-to-end distances, however were not observed until 70:1, which seem to suggest that further
binding of ΔMBD1 to nucleosomes can still occur beyond saturation. This seemingly contradictory
results may arise from the following two limitations of our current study, namely 1) the size of the
ΔMBD1-Nuc complex is not large enough to show an appreciable upward shift at higher ratios
(e.g., Nuc + 7 x ΔMBD1 and Nuc + 8 x ΔMBD1 may not be distinguishable); and 2) the current
Hill equation assumes similar affinities among different binding sites. At a high protein ratio,
ΔMBD1 will start to bind to hard-to-reach sites (e.g., neighboring meCG sites (arising from steric
hindrance) or meCG facing away from the octamer surface), bindings of ΔMBD1 to these hardto-reach sites are likely to be the direct course of the observed conformational change, while
ΔMBD1-binding to easily-accessible sites is unlikely to perturb the nucleosome conformation.
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Conclusions
Our study addresses the binding of the methyl binding domain of MBD1 to methylated
nucleosomes in the context of different CpG patterns. ΔMBD1 binds preferentially to methylated
nucleosomes. We have demonstrated that the positions of different methylated CpG sites play an
important role in determining the binding affinity. Binding of ΔMBD1 to nucleosomes shows
positive cooperativity. Significant conformational changes of nucleosomes were observed
particularly in nucleosomes containing
results suggest that

me

me

CpG sites facing away from the histone octamer. Our

CpG pattern embedded in genome can be differentially recognized by an

epigenetic reader domain, i.e., ΔMBD1. At 10 bp intervals, the (CGX8)5,towards, the most frequently
observed methylation pattern in the human genome116 is a potentially preferred substrate than the
(CGX8)5,away for methyl binding domains proteins such as MBD1. Our in vitro findings provide
an interesting ground-work for further studies probing the functional relevance of MBD1 in situ
or in vivo.
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Supporting Materials
3.10.1 Supporting tables

Table 3.10.1: Amino acid sequence of the modified ΔMBD1 with an additional C terminal
cysteine to add a fluorescein-5-maleimide (FAM) label to the protein.
Protein
FAM-labelled
ΔMBD1
(89 aa)

Amino acid sequence
10
20
30
40
50
60
MAEDWLDSPA LGPGWKRREV FRKSGATAGR SDTYYQSPTG DRIRSKVELT RYLGPAGDLT
70
80
LFDFKQGILG GGGTGGGGSL EHHHHHHHC

Table 3.10.2: The fitting values obtained after selectively eliminating points at higher
[ΔMBD1] : [Nucleosome] ratios and re-fitting the remaining points (See Fig. S13). The new Kd
and Hill coefficient values have been compared to the original fitted values and are
close/identical in value to the original.
Construct
(CG)5 – original fitting
A1
A2
A3
(CGX8)5,away – original fitting
B1
B2
B3

Kd (µM)
1.1 ± 0.2
1.2 ± 0.2
1.2 ± 0.1
1.2 ± 0.2
2.8 ± 0.2
2.5 ± 0.1
2.4 ± 0.3
2.7 ± 0.3

Hill coeffecient
4.2 ± 0.2
4.2 ± 0.2
4.2 ± 0.1
3.0 ± 0.2
0.9 ± 0.1
0.9 ± 0.2
0.9 ± 0.2
0.9 ± 0.1

R2 of fit
0.95
0.99
0.97
0.97
0.97
0.94
0.96
0.99
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3.10.2 Supporting methods
3.10.2.1 DNase I hypersensitivity assay
Nucleosomes were reconstituted from DNA containing a fluorescein-label. A 1:20 dilution of
DNase I (New England Biolabs) was used to digest ~ 5 µM of nucleosomes at 37 ˚C following an
established protocol119. To validate the positioning of the nucleosome and characterize the
potential resolution of our denaturating gel, we prepared control nucleosomes with a 5 bp offset
from

the

original

157

bp

nucleosomes

(DNA

sequence:

5’-

ACTCCCTGGAGAATCCCGGTGCCGAGGCCGCTCAATTGGTCGTAGACAGCTCTAGC
ACCGCTTAAACGCACGTACGCGCTGTCCCCCGCGTTTTAACCGCCAAGGGGATTAC
TCCCTAGTCTCCAGGCACGTGTCAGATATATACATCCTGTGCAGTGTTAC- 3’, with a
FAM label on the 5’ end of the complementary strand and the linker sequence underscored).
Samples were mixed with formamide and boiled for 10 minutes before loading onto a 20%
denaturating polyacrylamide gel (19:1 Acrylamide/Bis, 8 M Urea). The gel was run at 550 V for
30 minutes in a 1× TBE buffer. Visualization of the bands was performed using a Kodak imaging
station. A single stranded DNA ladder was included and stained with Stains-All (Millipore Sigma).
The results of the DNase I digestion are included in Fig. 3.10.5
3.10.2.2 Preparation of fluorescently labeled ΔMBD1
Fluorescently labeled ΔMBD1 (used in the Fluorescence Correlation Spectroscopy study) was
prepared by first mutating out all cysteine residues (C8S, C28A and C56G). The target amino acid
sequence was selected based on the consensus sequence of ΔMBD1127. An additional cysteine
residue was introduced to the C terminus via site-directed mutagenesis (see Table 3.10.2). The
mutant ΔMBD1 was labeled using fluorescein-5-maleimide following our established protocol and
showed similar binding affinity to methylated DNA as demonstrated previously120.
3.10.2.3 Fluorescence correlation spectroscopy (FCS)
FCS was used to characterize the binding between ΔMBD1 and nucleosomes at low
[ΔMBD1]:[Nuc] ratios. The binding reaction was carried out using similar buffers as in EMSA.
Labeled ΔMBD1 was mixed with nucleosomes at the same molar ratios used in EMSA, while
nucleosome concentration was kept constant. All FCS measurements were performed at room
temperature using an ALBA FCS dual-channel confocal spectrometer (ISS, IL). The detailed
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microscopy setting was described previously 84,132. The correlation curves (G(τ)) of each sample
were collected and then analyzed using VistaVision Software (ISS, IL) via a two-species model as
shown in Eq.S1.
S
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Eq. S1

where N is the average number of fluorescent molecules within the focal volume, τ is time, f1
is the fraction of unbound (free) ΔMBD1, and wo (=zo/ro) is an axial (zo) to lateral (ro) dimension
ratio, characteristic of the confocal volume. The values of wo were calibrated using a standard
Rhodamine 110 solution (D=430 µm2/s)

133

. D1 and D2 is the diffusivity of bound and unbound

ΔMBD1, respectively. Typical correlation curves along with their fittings are shown in Fig. 3.10.6.
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3.10.3 Supporting figures

(A)

(B)

Figure 3.10.1: (A) BstUI restriction enzyme digestion pattern of 0 and 100% methylated DNA.
The endonuclease activity of BstUI is completely blocked by CpG methylation. B) A typical 6%
PAGE showing unlabeled and donor (FAM)-labeled DNA samples.
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Figure 3.10.2: A 5% polyacrylamide gel showing the reconstituted nucleosomes used in this
study. The [Octamer]:[DNA] ratio was optimized to ensure absence of unbound DNA.
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Figure 3.10.3: A 5% polyacrylamide gel showing reconstituted nucleosomes with different linker
lengths. N is original Widom 601 positioning sequence. The 6-N-6 linker configuration migrates
faster than the staggered 0-N-12 and the bands are at distinctly different positions in the gel.
Intermediate configurations (such as 4-N-8) would theoretically be located in zone between the
6-N-6 and 0-N-12. A 1-N-1 nucleosome reconstituted from 145 bp DNA was included as a
reference. The original sequence N is as follows:
TGGAGAATCCCGGTGCCGAGGCCGCTCAATTGGTCGTAGACAGCTCTAGCACCGCT
TAAACGCACGTACGCGCTGTCCCCCGCGTTTTAACCGCCAAGGGGATTACTCCCTA
GTCTCCAGGCACGTGTCAGATATATACATCCTG. The 6 bp flanking sequences in 6-N-6
are ACTCCC and TGCAGT on the left and right of N respectively. The 12 bp linker sequence in
0-N-12 is TGCAGTGTTACT and the additional 1 nucleotide in the 1-N-1 configuration is C-NT.
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Figure 3.10.4: A plot of the probability of nucleosome occupancy against the position of the
DNA bases predicted using an online nucleosome positioning tool, developed by van der Heijden
et. al. 79. The tool predicts that once reconstituted, the differences in the DNA sequences of the
four constructs used in this study do not cause any change in the linker DNA length of the
reconstituted nucleosomes, although the probability of nucleosome occupancy in the 4 constructs
differs based on the DNA sequence
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Figure 3.10.5: (A) A 20% denaturing polyacrylamide gel was used to assay the four nucleosome
samples digested with DNase I. The nucleosome and DNA samples were labeled with a FAM
dye. The ladder is a mixture of single stranded DNA fragments and was visualized using StainsAll. An additional nucleosome control (Offset nucleosome) that is offset from the original 157
bp nucleosome by 5 bp (6-N-12) was included in this gel. The Offset nucleosome is expected to
exhibit a 5-base shift compared to the control nucleosome in their DNase I digestion patterns. In
(B), the band intensities of the four nucleosomes (Control, (CG)5, (CGX8)5,away and
(CGX8)5,towards) are plotted along with the Offset nucleosome. All four nucleosomes used in our
study exhibited a similar digestion pattern with almost identical pixel traces as shown in (B)
suggesting that the contact points of the DNA to the octamer surface are almost the same among
all constructs. The Offset nucleosome exhibits a distinctive digestion pattern clearly
demonstrating the ability of our gels to resolve contact-point-shifts larger than 5 bases.
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(A)

(B)
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Figure 3.10.6: Sample correlation curves of bound ΔMBD1 at [ΔMBD1] : [Nucleosome] = 1:1.
Top: a sample autocorrelation function of methylated Control nucleosomes and its fitting (D1=
111.3 µm2/s, D2= 36.9 µm2/s, f=0.87 and χ2= 1.5). Bottom: a residual plot suggesting the
residual trace was randomly distributed.
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Figure 3.10.7: The concentration of free ΔMBD1 when ΔMBD1 and nucleosomes were mixed at
an equal molar ratio. The findings from FCS and EMSA were compared and found to be not
statistically different from each other (Student’s t-test, 95% confidence interval). Data = mean ±
standard deviation, n= 2-3.

58

Figure 3.10.8: Anisotropy values of donor or acceptor labeled Control DNA reconstituted into a
nucleosome form. The DNA is either 0 or 100% methylated.
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Figure 3.10.9: Binding pattern of ΔMBD1 to unmethylated nucleosomes under selected ratios.
Under the highest [ΔMBD1]/[Nuc] ratio tested (see also Fig. 2A), no significant upper bands
(slow-moving) corresponding to ΔMBD1-nucleosome complexes were visible.
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(A)

Ladder

Slice1

Slice 2

(B)
Ladder

Slice1

Slice 2

Figure 3.10.10: Western blot analysis of Slices 1 and 2 (as illustrated in Fig. 3.4.1(A)) using
antibodies specific for (A) the 6 × C-terminal His-tag on the ΔMBD1 protein (Life Technologies,
Grand Island, NY) and (B) Histone H4 (Active Motif, Carslbad, CA).
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(A) Control

(C) (CGX8)5,away

(B) (CG)5

(D) (CGX8)5,towards

Figure 3.10.11: Individual binding curves for the four nucleosomes used in this study.

62

Figure 3.10.12: Typical DNA PAGE showing DNA (methylated) and ΔMBD1 binding results at
different protein to DNA ratios.
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(A1)

(A2)

(A3)

(CG)5

(B1)

(CGX8)5,away

(B2)

(B3)

Figure 3.10.13: To verify the robustness of our fitting results for the constructs (CpG)5 and
(CGX8)5,away as shown in Table 3.3.1, we eliminated selective points at a high protein-to-DNA
ratio (where a large measurement error will be anticipated) and analyzed the points left. The
fitting results as shown in A1-3 and B1-3 for successive eliminations are summarized in Table
3.10.2 and do not change appreciably from the original numbers reported in Table 3.3.1.
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Figure 3.10.14: Binding assays were repeated at lower nucleosome concentrations for two of the
constructs for further validating the Hill equation fitting. Nucleosome concentrations in this
assay are 0.1 µM as compared to the 0.4 µM used in the main text. The Kd values and Hill
coefficients for the (CGX8)5,away are 2.8 ± 0.1 and 1.2 ± 0.1 and the Kd values and Hill
coefficients for the (CG)5 construct are 0.8 ± 0.2 and 3.7 ± 0.3. Data = mean ± S.D. (n=3).
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Figure 3.10.15: Energy transfer efficiency of FRET pairs introduced to the ends of varying DNA
constructs as a function of varying [ΔMBD1] : [Nuc] ratios. Inset: schematic illustration of the
location of FRET dyes.
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4. FLOW CYTOMETRIC SORTING OF LIVE MAMMALIAN CELLS
BASED ON EPIGENETIC MODIFICATION LEVELS

Abstract
Tumor cells are intrinsically heterogeneous in nature, exhibiting variations at both the genetic and
epigenetic levels. The epigenetic signature of cancer cells varies with disease progression and drug
treatment, necessitating the study of these modifications with single cell resolution over time. The
rapid detection of epigenetic modifications by flow cytomtery is a powerful approach that can
provide single cell measurements. It is mainly accomplished by the use of antibodies specific to
the modifications allowing the quantification of tumor heterogeneity linked modifications such as
DNA methylation and H3K9me3. Repressive epigenetic modifications, however, are present in
highly condensed chromatin causing ineffective binding of the antibody. Moreover, dynamic
monitoring of cells following drug treatment is not possible due to the requirement of fixation and
cross-linking steps. The probes developed and employed in this study offer single, live cell
tracking capability with comparable spatial and quantitative accuracy to commercial antibodies.
We managed to sort cells based on their epigenetic contents. The sorted cells are viable and exhibit
distinctive responses to drugs and growth rate. Notably, subpopulations of MCF7 cells with higher
5mC levels is less resistant to Doxorubicin treatment and grows less aggressively. Subpopulations
of MCF7 cells with higher H3K9me3 levels are more resistant to Doxorubicin treatment while
forming less aggressive tumors. Overall, we report for the first time, the use of a live cell
compatible flow cytometry approach to rapidly sort cells based on their epigenetic background
with applications towards dissecting epigenetic contributions to tumor heterogeneity.

Introduction
Epigenetic modifications overlying the genome control a host of cellular processes
involved in development and differentiation. Common epigenetic modifications include DNA
methylation (i.e., methylation at 5-cytosine (5mC)) and various histone post-translational
modifications (i.e., methylation and acetylation of lysine and arginine residues). Epigenetic
modifications are affiliated with distinctive gene activity (transcription “on” or “off”). For example,
5mC is commonly found in the context of CpG dinucleotides134 and is responsible for genomic
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imprinting93, X chromosome inactivation and silencing of repetitive elements135. Trimethylation
of lysine 9 of histone H3 is an important repressive mark that is commonly found in gene-poor
regions and is associated with satellite repeats136 and retrotransposons137. Aberrant changes in
epigenetic modifications are commonly observed in various types of cancers, such as leukemia,
breast, lung and colon cancer138,139.
Accumulating literature suggests that apart from genetic changes (reviewed in140),
epigenetics also contribute significantly to cancer initiation and progression141. Specifically, the
differences in epigenetic modification levels can also partially account for tumor heterogeneity,
which may ultimately result in the differential persistence and response of tumor cells to drug
treatment142–145.

The

exact

connection

between

epigenetic

modifications

and

drug

response/resistance, however, remains elusive since epigenetic variations are innate to cultured
cells and it is thus difficult to dissect their contributions due to intrinsic heterogeneity. To address
this, we need to sort cells based on their variable epigenetic background, track sorted cell
population via continuous culturing and subsequently establish the connection between epigenetic
modification levels and cell functionality.
Fluorescence assisted cell sorting (FACS) can be applied readily to address the first of
these challenges. Antibodies specific to DNA methylation146,147 and histone modifications33 have
been applied to fixed cells and enabled the quantification of epigenetic modifications in cancer
cells. For instance, flow cytometry protocols for fixation and antibody staining of H3K27me3 and
H3K9me3 were developed by Watson, et al33 and were used to assay these modification levels in
clinical samples from leukemia patients. First, these studies confirmed that epigenetic
heterogeneity is a common observation in tumor sample. However, several major concerns remain.
The development of these and other antibody-based protocols requires significant optimization to
ensure that the fixation method does not alter cellular morphology. When identifying repressive
modifications present in condensed chromatin, epitope masking34(loss of binding sites due to lack
of accessibility) can be a very significant concern. Most importantly, antibody-based sorting
approaches, are limited to fixed cells and thus precludes dynamic tracking of the sorted cell
population. There are no live-cell compatible epigenetic sorting tools to the best of our knowledge.
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The limitations of using antibodies to track epigenetic modifications over time, extends to
other platforms such as microscopy, as well. Recently, a few tools have been developed to
overcome these limitations, such as live cell compatible Fab based probes148,149 and FRET based150
approaches. Specifically, fluorescent labeled antigen binding fragments (Fab) have been used to
track H3K9 and 27 acetylation in live mouse embryo imaging148. The method can be extended to
study other histone posttranslational modification levels but requires the development and
characterization of highly specific monoclonal antibody fragments. The binding duration and
affinity of the Fab probes can also affect the readout of the dynamic change in modification levels.
Similarly, genetically encoded antibody based “mintbodies” have been generated to track
H4K20me1151 in mammalian and yeast cells. FRET based sensors for assessing intracellular
modification have been developed for H3K9me and H3K27me3152 as well as H4K5,8and 12
ac153,154. FRET interactions occur between donor and acceptor moieties which are connected by
an epigenetic modifying enzyme or reader and its target amino acid binding sequence. The FRETsensors can be used to quantify the modification level of the “reporter” histone but does not directly
inform the modification level of endogenous histones. In this work, we engineered probes that
recognize epigenetic modifications based on native epigenetic “reader” domains. Similar strategies
have been adopted by us120,155 and other groups111 and were shown to be effective in probing the
modification of interest with minimal perturbation of innate cellular functionality.
We have selected two epigenetic modifications, namely 5mC and H3K9me3 in this study,
because of their significant roles in cancer progression and disease development. The “reader”
domains chosen for recognition of DNA methylation and H3K9me3 are based on the methylbinding domain protein (MBD1) and the chromo-domain protein (CDY1) respectively.
Bimolecular fluorescence complementation (BiFC) was adopted to enhance the signal quality of
our probes. We demonstrate the use of these probes to sort cells based on their 5mC and H3K9me3
levels. Lastly, the contribution of epigenetic heterogeneity to drug resistance and tumor formation
was assessed using breast cancer cell lines.
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Materials and Methods
4.3.1 Design and validation of epigenetic probes
Full-length and BiFC epigenetic probes were designed as illustrated in Figs. 4.4.1(A) and 4.4.3(A).
The amino acid sequences of the “reader” domains are shown in Table 4.7.1. In situ probes were
subcloned into a PRK5 plasmid, while a bacterial expression vector was constructed using a
pET21b vector. A negative control was constructed similar to a full-length probe but without the
engineered “reader” domain.
4.3.2 Mammalian cell culture, transient transfection and drug treatments
HEK293T and MCF7 cells were maintained in DMEM (Dulbecco’s modification of
Eagle’s Medium) supplemented with 10% (v/v) fetal bovine serum (Atlanta Biologicals) and 1%
(v/v) of Penicillin-Streptomycin solution (Gibco, Grand Island, NY) in an atmosphere of 5% CO2
at 37˚C. Cells were grown in 100 mm tissue culture treated plates (Corning, Corning, NY) and
passaged every 2-4 days after reaching a confluency of ~ 80% following standard cell culture
protocols156. For microscopy-based analysis, cells were seeded onto ibidi 8 well µ slides (ibidi
USA, Fitchburg, WI).
Lipofectamine 3000 (Life Technologies, Carlsbad, CA) was used as the transfection
reagent to transiently transfect cells with plasmids encoding the probe, following manufacturer’s
protocols. Transfected cells were detached from the surface using TrypLE (~ 24 hours posttransfection) and resuspended in PBS, pH 7.4 with 1% BSA prior to FACS sorting. For culturing
cells on Matrigel (Catalog#356230, Lot# 6095004, Corning, Bedford, MA), 12 well plates were
coated with 50 µl of Matrigel and cells were seeded on to the solid gel.
Epigenetic drugs were used to perturb cellular epigenetic modification levels.
Specifically, BIX-01294 (Sigma, St.Loius, MO) a histone methyltransferase (G9a HMTase)
inhibitor157,158 was used to lower the H3K9me3 levels. The drug concentrations chosen for BIX01294 treatment were 3 and 5 µM respectively in order to minimize toxicity effects on cells157. A
DNMT1 inhibitor, RG108 was used at a concentration ranging from 10 - 100 µM to lower the
DNA CpG methylation level159,160. Epigenetic drugs were directly spiked into cell culture media.
Similarly, Doxorubicin exposure was performed at varying concentrations from 0-22 µM to
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assess the cytotoxic effects of this drug on MCF7 cells. All cells were exposed to drugs for a
minimum of 48 hours prior to analysis.
4.3.3 Fluorescence assisted cell sorting (FACS)
All flow cytometry data were collected using a BD FACS Aria (Becton Dickson, San Jose,
CA) with a 488 nm laser line and a 530/30 nm FITC filter. Un-transfected HEK293T cells were
used to determine the proper gating used in the analysis (see Fig. 4.7.1). All cytometry data was
analyzed using FCS Express software (De Novo software, Glendale, CA).
Cell sorting was performed using a BD FACS Aria III Cell sorter. The sorter is equipped
with temperature control and a biosafety cabinet to ensure sterility of the cell samples pre- and
post- sorting. Similar gating strategy as described above was used.
4.3.4 Microscopy imaging
Cell imaging was performed on a Nikon Eclipse Ti-E microscope equipped with a 60× oil
immersion objective lens and automated stage.
4.3.5 Immuno-staining
Transfected cells can be fixed and then immune-stained with commercial antibodies using
our established protocol161. Commercial antibodies (anti-H3K9me3, ab8898, + Goat-anti-rabbit,
Alexa Fluor 568 (Abcam, Cambridge, MA), and anti-5mC, #61256 (Active motif, Carlsbad, CA)
+ Donkey-anti-mouse Alexa Fluor 647) were used in the validation.
4.3.6 Quantifying cellular epigenetic levels using ELISA
ELISA assay kits were used to assess the global epigenetic changes in cell population.
Genomic DNA was extracted using a Genomic DNA Extraction kit (Invitrogen). Histones were
extracted following an acid extraction procedure. The Global DNA methylation kit, H3K9me3
ELISA and total histone H3 ELISA kits (Active Motif, Carlsbad, CA) were used to assay the DNA
methylation, H3K9me3 and histone H3 levels, respectively.
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4.3.7 Data analysis and statistics
ImageJ plugin JACoP was used to determine the co-localization of probe-transfected and
immuno-stained images. Fluorescence intensity per nuclei (FIPN) were analyzed via a customized
pipeline written using Cellprofiler. For all image analysis, more than 100 cells were analyzed from
> three independent repeats. All ELISA experiments were carried out using n=3 or 4 biologically
independent samples in duplicate. FCS Express software (De Novo software, Glendale, CA) was
used to generate the intensity histograms.
All statistical analysis and error propagation calculations were performed using Graphpad
Prism by an ANOVA analysis followed by post-ANOVA testing using Tukey’s test, considering
p < 0.05 to be statistically significant. Origin Pro and Graphpad Prism were both used for creating
figures and graphs.

Results and Discussion
4.4.1 Validation of epigenetic probes in situ
The general design of the in-situ probes is illustrated in Fig. 4.4.1(A). Different probe
designs were screened. Among them, homo-dimeric proteins consisting of two “reader” domains
connected via a flexible linker (G4S) were found optimal in probing endogenous epigenetic
changes. The “reader” domains were selected based on chromodomain of the human CDY family
of proteins162 and the methyl binding domain (MBD) of the human MBD1109,120,161 for probing
H3K9me3 and 5mC, respectively. The detailed amino acid sequence of our probes can be found
in Table. 4.7.1.
Engineered H3K9me3 probes can be transfected into cells (e.g., HEK293T), translocate
into cell nucleus and exhibit the expected binding patterns (see Fig. 4.4.1(B)), with a rim of
H3K9me3 enriched at the nuclear periphery and large islands of H3K9me3 corresponding to perinucleolar heterochromatin163. Co-staining with a commercial antibody was performed to validate
that the spatial distribution of the H3K9me3 sensor corresponds to the endogenous H3K9me3 sites
(Fig 4.4.1(B), bottom).
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Figure 4.4.1: (A) Schematic of probe design showing the nuclear localization signal (NLS) at the
N-terminal and the mEGFP at the C-terminal of the probe. Straight lines indicate flexible G4S
linkers. B) Top panel: Live cell images of HEK293 cells were transfected with the H3K9me3
probe. Bottom panel: Representative images of the binding pattern of the H3K9me3 probe with
commercial Anti-H3K9me3 antibody shows perfect co-localization. C) Top panel: Live cell
images of HEK293T cells expressing the 5mC probes and showing the characteristic pattern of
DNA methylation. Bottom panel: Anti-5mC antibodies and the 5mC probes have similar binding
patterns (note that these images are not from the same cell). D) BIX01294 a G9 HMT inhibitor
was used to lower the H3K9me3 levels and the change was captured by the H3K9me3 probes.
Inset: typical z-stack projection of BIX01294 treated cells. ELISA for H3K9me3 was conducted
to verify the decrease in H3K9me3 levels. (E) Decrease in DNA methylation level induced by
RG108 (a DNMT1 inhibitor) was captured by the 5mC probe as quantified by the decrease in
mean foci intensity per nulcei. Inset: typical z-stack projection of RG108 treated cells. An
ELISA based approach was used to validate the activity of RG108 in HEK293T cells. Data
represents n=100 cells for microscopy-based analysis and n=4 for ELISA; error bars represent
standard deviations. * indicates a statistically significant difference between samples at a p<0.05
and was calculated by a one-way ANOVA analysis followed by Tukey’s test for post-hoc
comparison of means.
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Pixel-by-pixel co-localization analysis reveals that the Mander’s correlation coefficients
(M1 and M2) are both close to 1 (M1= 0.917 ± 0.08 and M2= 0.915 ± 0.11), indicating a strong
positive correlation (see Fig. 4.7.2(A)). The protein probe was also expressed recombinantly and
was found to be highly specific for H3K9me3 compared to wild-type H3 (see Fig. 4.7.3(A)),
binding with an affinity of 0.16 ± 0.02 µM (see Fig. 4.7.3(B))
Our previous work has shown that the methyl binding domain (MBD) of the human MBD1
protein can be used to detect CpG methylation120. A similar design has been demonstrated in
literature as a viable approach for detecting DNA methylation111, but without offering live cell
compatibility. Transfecting the 5mC probes into human cells enables in situ visualization of DNA
methylation (see Fig 4.4.1(C), top). The 5mC probes exhibit similar fluorescence patterns as
compared to a commercial antibody (see Figs. 4.4.1(C), bottom and 4.7.2(B)), showing small
bright foci of DNA methylation111,164. Unlike our 5mC probes, commercial 5mC antibodies only
recognize 5mC in a single-stranded form. A harsh acid DNA denaturing step is thus required postfixation which displaces a large amount of 5mC probes and renders the co-localization approach
described above infeasible. To compare the pattern obtained, we collected a large number of cell
images (n>100), extracted pattern features and performed a principal component analysis to
determine any features that can be used to distinguish images obtained from our 5mC sensor and
the antibody. These two types of images were found indistinguishable in the principal component
space (see Fig. 4.7.2(B)) and thus can be considered statistically similar to each other.
4.4.2 Quantification of epigenetic changes based on fluorescent intensity
To determine the quantitative accuracy of our probes, cells of varying epigenetic
modification levels were required. HEK293T cells were thus treated with epigenetic drugs of
selected concentrations. Specifically, BIX01294, a histone methyltransferase inhibitor was used to
lower the H3K9me3 levels. A DNMT1 inhibitor, RG108, was used to lower the DNA methylation
level159,160. The treatment concentrations of [BIX01294] = 3 and 5 µM and [RG108] = 50 and 100
µM were chosen to induce significant changes in the modification levels while keeping cell
viability and phenotypic features intact based on existing literature158,160. treated cells were imaged
via fluorescence microscopy and immediately lysed and assayed via ELISA to determine their
respective changes in epigenetic modifications.
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The fluorescence intensity per nuclei (FIPN) above the diffusive background is expected
to be proportional to the number of probes binding to their targets and thus the endogenous
modification levels. 2D projection of z-stacks of cells were used in the analysis. Typical images
of cells under different treatment conditions can be found in Figs. 4.4.1(D) and (E) and Fig. 4.7.4.
Fluorescence images were collected and analyzed. The measured mean FIPN values were used to
determine the relative changes in H3K9me3 and 5mC due to treatments. The results were
compared to those from ELISA as shown in Figs. 4.4.1(D) and (E). Under BIX01294 treatments,
the values of FIPN decrease with increasing BIX01294 concentrations. Similar results were
obtained using ELISA. The relative change in H3K9me3, as measured by the H3K9me3 probe and
ELISA, are found to be in close accordance with each other at defined drug concentrations. The
FIPN intensity and ELISA values at the increasing BIX01294 concentration have a negative
Pearson’s correlation coefficient (r = -0.99) as expected. 5mC probes claim a similar quantitative
accuracy. Specifically, FIPN and ELISA of 5mC probes shows a strongly negative correlation (r
= - 0.99) with RG108 concentrations as expected. The relative changes in DNA methylation level
calculated based on FIPN shows a close correlation with findings from ELISA.
Overall, both the H3K9me3 and 5mC sensors demonstrate the expected binding pattern to
their target epigenetic modifications. The quantitative changes in these modifications induced by
specific inhibitors can be monitored using our sensors with a comparable accuracy to commercial
immunoassays. While microscopy is a useful starting point to demonstrate the feasibility of the
probes for quantifying and tracking epigenetic modifications, intensity- based analysis relies on
acquiring confocal microscopy images of n >100 cells and does not allow us to easily isolate cells
based on their epigenetic modifications. A complicated approach, i.e. microdissection165 can be
potentially used but is not practical for the collection of a large number of cells. We therefore
tested the application of our sensors on a relatively high-throughput platform, namely fluorescence
activated cell sorting (FACS).
4.4.3 Analysis and sorting of cells based on their epigenetic modification level.
Moving towards a FACS platform, we want to demonstrate that 1) the intensity histogram
obtained from FACS can be used to quantify changes in epigenetic modification levels; and 2) the
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sensor can be used to sort cells into different subpopulations with distinctive epigenetic
modification levels.
To address the first point, H3K9me3 and 5mC probes were individually introduced into
cells of distinctive epigenetic modification levels (induced by inhibitor treatment similar as
described above). Transfected cells were analyzed using FACS to generate distinctive intensity
histograms as shown in Figs. 4.4.2(A) and 4.4.2(C). Median fluorescent intensity (MFI) was
determined from the histogram and used to quantify average changes in fluorescence intensity
corresponding to epigenetic changes. The findings were compared to ELISA as shown in Figs.
4.4.2(B) and (D). Upon BIX01294 treatment, the intensity histogram shows a left-ward shift,
suggesting the loss of highly fluorescent species corresponding to cells with high H3K9me3 levels.
BIX01924 can result in the loss and shrinkage of H3K9me3 islands (see Fig. 4.7.4(A) based on
our microscopy studies. The observed histogram change thus reflects well with our previous
observations. As a result, the measured MFI values decrease with increasing drug concentrations.
To account for the potential influence of BIX01294 on total protein expression level, we
constructed a negative control (NC) similar to our probes but without the engineered “reader”
domains (schematic shown in Fig. 4.7.5). The fluorescence histogram of NC under varying
BIX01294 concentration is shown in Fig. 4.7.5(A) with MFI shown in Fig. 4.7.5(B). Increasing
BIX01294 concentrations slightly increase protein expression level. The changes in intensity
arising from BIX treatments, however, is of an opposite trend to what we observed in H3K9me3
changes, suggesting that we can reliably pick up qualitative changes in H3K9me3 levels via the
collected intensity histogram and MFI. To account for changes in probe expression levels, we
corrected MFI via respective changes in expression levels using values plotted in Fig. 4.7.5(B).
Similar to MFI, corrected MFI decreases with increasing BIX01294 concentrations, but shows a
closer match with findings from ELISA. For example, at [BIX01294] = 5 µM, the relative changes
in H3K9me3 as determined using MFI, corrected MFI and ELISA was found to be 82%, 71% and
65%, respectively. The corrected MFI are closer to the ELISA values, but still underestimates the
change in H3K9me3 level upon drug treatment. Additionally, the uncorrected MFI at [BIX01294]
= 3 and 5 µM are not statistically different from each other while the corrected MFI value can
distinguish between these two treatment cases.
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Figure 4.4.2: The mean fluorescent intensity (MFI) captures the signal arising from both bound
and unbound GFP population and is used to quantify the epigenetic modification levels. In (A),
Histograms of the fluorescent intensity at differing drug concentrations are provided. Straight
lines within the histogram represent the intensities from which the sorted populations were
derived. In (B), the H3K9me3 probe captures the relative levels of H3K9me3 in cell population
exposed to increasing concentrations of BIX01294. Corrected MFI values are obtained from a
GFP only control plasmid and are compared to ELISA based methods. (C) and (D) Similar
results are seen for the 5mC probe upon RG108 treatment with the MFI decreasing as the drug
concentration increases. Histogram peaks are shifted downwards at increasing RG018
concentrations. Data is collected from n= 3 biological repeats for ELISA and FACS, assaying
1,000,000 cells for each round of FACS. The error bars represent standard deviation. * indicates
a statistically significant difference between samples at a p<0.05 and was calculated by a oneway ANOVA analysis followed by Tukey’s test for comparing means
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Treating cells with RG108 gives rise to distinctive intensity histograms that presumably
reflect the distribution of 5mC in HEK293T cells as shown in Fig. 4.4.2(C). Higher RG108
concentrations result in the diminishing of high fluorescent intensity peaks in the histograms. MFI
and corrected MFI both decreases with increasing [RG108] as shown in Fig. 4.4.2(D), while
corrected MFI values more faithfully mirror DNA methylation changes in cell populations as
measured via ELISA similar to observations above. Collectively, our results suggest that FACS
analysis can reasonably capture quantitative changes in epigenetic modification levels upon drug
treatment.
To address the latter point and further validate that the measured intensity histogram may
reflect the distribution of epigenetic changes among cell population, we sorted cells (transfected
but untreated) into distinctive sub-populations based on fluorescence intensity. Three subpopulations, namely, Low, Medium and High were defined based on fluorescence intensities based
on the capability of a BD FACS Aria III Cell Sorter (vertical lines on the intensity histograms in
Fig 4.4.2(A) and (C) identify the gates for binning the cells). Sorted cells were analyzed to reveal
their epigenetic modification level via ELISA as shown in Figs. 4.4.2(E) and (F); and can also be
reseeded into a culture dish for continuous monitoring as shown in Fig. 4.7.6(A) and are viable
after sorting (Fig. 4.7.6(B)). Reseeded cells exhibit the expected fluorescent intensity variations
and maintain these characteristics for at least 48 hours post-sorting. Changes were observed among
sorted subpopulations. Specifically, the High species sorted based on H3K9me3 probe exhibited
25.58% increase in H3K9me3 levels compared to the Low Species. No significant H3K9me3
changes, however, was observed between the Low and Medium populations. Similar observations
were made in cell populations sorted via the intensity of 5mC probes. Our findings thus suggest
that although we can sort cells into different epigenetic modifications at high fluorescence intensity,
equivalent to cells expressing a large amount of our probes, the distinction of cell populations at
low to medium fluorescence intensity is not adequate. The loss of sorting resolution is likely to
arise from variations in probe expression levels, i.e., non-uniform distribution of fluorescent
molecules within cells166, that subsequently contribute to the background and loss of resolutions
at low fluorescence intensities. Although the resolution from our sorting is suboptimal (possibly
due to the background of freely diffusing GFP), we managed to sort cells into two distinctive
populations with varying epigenetic modifications levels.
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4.4.4 Improve cell sortability via BiFC
To improve the sortability of our probes and ease the burden in interpreting the intensity
histogram from our FACS analysis, a bimolecular fluorescence complementation (BiFC) approach
was adopted. BiFC strategy relies on fluorescence complementation between two fragments of the
GFP protein which generates the full-length fluorophore167,168. Since individual N- or C- terminal
fragments are non-fluorescent, signal is only obtained when the two halves are in close proximity
and can generate the full- length GFP. This strategy can thus significantly reduce background169–
171

and potentially addresses the issues that we encountered above.
A schematic illustration of our BiFC probe design is presented in Fig. 4.4.3(A). The N-

and C-terminal probes were not individually fluorescent but fluoresce when co-transfected into
cells (see Fig. 4.7.6(A)). Probes employing the BiFC strategy are henceforth referred to as
“H3K9me3 or 5mC split-probes”. Transfected cells were subject to similar FACS analysis and
sorting as described in the previous section. Intensity histogram of cells sorted under different drug
conditions (see Figs. 4.4.3(B) and (C)) exhibited the expected trend with drug treatments resulting
in a significant reduction of the abundance of high fluorescent (also high modification level)
species. Cells exhibited a bimodal distribution in both H3K9me3 and 5mC levels similar to what
was previously observed using full-length probes but with more defined peak features. MFI and
corrected MFI were compared to findings from ELISA as shown in Figs. 4.4.3(C) and (E). A
closer matching was observed between relative epigenetic changes calculated based on MFI (as
well as corrected MFI) and ELISA findings, suggesting improved signal quality using the BiFC
probe sets.
Cells were sorted into Low, Medium and High bins similar as described previously for fulllength probes. Sorted cells can be reseeded into a culture dish and imaged as shown in Fig 4.7.6(A).
Reseeded cell populations retained the expected variations in fluorescence intensity and were
viable for at least 24 hours after seeding. Part of the cells were immediately lysed and analyzed
using ELISA. Statistical significance was observed among the Low, Medium and High
subpopulations, revealing enhanced capability of BiFC probes in sorting cells based on epigenetic
modifications.
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Figure 4.4.3: (A) Schematic of the BiFC strategy used to modify the probes. in (B) and (C),the
GFP intensity histograms as well as the corrected and MFI values demonstrate the ability of the
split-probes to quantify the changes in H3K9me3 levels. In (D) and (E), the 5mC probe is used to
quantify the DNA methylation levels. In (F) and (G), the epigenetic background of H3K9me3
and DNA methylation can be identified using the split probes. Data is representative of n=3
biologically independent repeats for the ELISA and FACS samples, error bars indicate standard
deviation. * represents p<0.05 and ** represents p<0.01 from a One-way ANOVA followed by
Tukey’s post hoc.
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Collectively, we have identified that BiFC-based epigenetic probes can offer improved
quantitative accuracy in gauging the epigenetic distribution among cell populations and enable cell
sorting with an enhanced resolution. It is worth noting, however, there are a few drawbacks
compared to the full-length probes. First, the dimerization of BiFC probes is not instantaneous and
renders immediate readouts infeasible172. Second, the BiFC probes require co-delivery of two
plasmids that typically result in low transfection efficiency and thus can be less efficient in
recognizing cellular heterogeneity using a complex cell mixture (e.g., cells harvested from
patients). The whole probe offers distinct advantages in this regard. We proceeded with both whole
and BiFC probes in evaluating how epigenetic modifications affect drug resistance and tumor
evolution in breast cancer cell lines.
4.4.5 Distinct epigenetic contributions to tumor heterogeneity in breast cancer cells.
Epigenetic modifications are heavily linked with tumor heterogeneity in almost all types
of cancers and eventually contribute to differences in drug resistance173,174 and tumor evolution6,175.
Limited tools exist for profiling the epigenome or for sorting cells based on their epigenetic
background to further our understanding of tumor heterogeneity141. We thus applied the probes
developed in this work towards sorting and analyzing cancer cells for their potential drug
resistance and ability to form tumors.
A widely known example of drug resistance is the application of anthracycline drugs, (e.g.
Doxorubicin), in breast cancer treatments176,177. Drug resistance to Doxorubicin can develop in
many patients of breast cancer, leading to persistence of tumors or cancer relapse. Several
mechanisms are implicated in the development of resistance, including epigenetic factors such as
DNA methylation and histone modifications. For instance, the Doxorubicin resistant version of
the breast cancer cell line MCF7, is characterized by global hypomethylation and
hypermethylation at specific gene promoters178,179. We tested the use of the whole and BiFC probes
in Doxorubicin cytotoxicity assay in MCF7 cells to evaluate how the epigenetic background
contributes to Doxorubicin resistance of MCF.
We measured the cell viability of the MCF7 cell line as well as MCF7 cells sorted into low,
medium and high species. To begin, we evaluated the viability of MCF7 cells under varying
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Doxorubicin concentrations as shown in Fig 4.7.7. At a drug concentration of ~ 0.9 µM, 50% of
the cells undergo apoptosis measured via an MTT assay. Similar assays were performed using
MCF7 cells sorted into Low, Medium and High H3K9me3 or 5mC levels based on our sorting
platform. These cells were then seeded onto tissue culture plates and then exposed to two
concentrations of Doxorubicin (0.5 and 1 µM) for 48 hours. The cell viability was measured by an
MTT assay after drug exposure and the data is showed significant variations among different
epigenetic groups as illustrated in Fig. 4.4.4. Appreciable differences in cell viability were not
noticed at a Doxorubicin concentration of 0.5 µM. At the higher exposure dose, however, the cell
viability differs significantly.
In Fig. 4.4.4(A) and (C), the H3K9me3 whole- and split-probe both show lower toxicity
for the High species, indicating that a lower H3K9me3 level offers less resistance to Doxorubicin
treatment. The cytotoxicity in the High bins is lower as compared to the Low and Medium bins.
The split probes offer slightly better resolution in differentiating the three populations from each
other (Fig. 4.4.4(C)), but the same trend persists. Combined, our results suggest that high
H3K9me3 seems to contribute to Doxorubicin resistance in MCF7 cells. The underlying
connection between histone methylation and Doxorubicin resistance in breast cancer cells is still
poorly understood. There is some evidence from acute leukemia cells suggesting that certain
histone modifications (including H3K9me3) are enriched in Doxorubicin resistant versions of the
leukemia cells180. Antibody based analysis of histone modification levels of a doxorubicin resistant
version of MCF7 potentially indicate the H3K9me3 levels between the two versions are not
significantly altered181. Our data, however, suggests that elevated levels of H3K9me3 might
potentially be linked to development of Doxorubicin resistance in MCF7 cells.
In case of DNA methylation, we observed the opposite trend, with low levels of DNA
methylation corresponding to lower cytotoxicity (Fig. 4.4.4(B) and (D)). The results from both
versions of the probe are in agreement, with the 5mC BiFC probe providing significant differences
between the three epigenetic bins. Our data suggests that a low DNA methylation level (5mC)
might correspond to lower cytotoxicity upon Doxorubicin exposure indicating a higher degree of
drug resistance. Numerous studies have highlighted similar findings178,179,182 in Doxorubicin
resistant versions of MCF, showing global DNA hypomethylation in these cells.
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Figure 4.4.4: (A) The addition of Doxorubicin to sorted cell populations expressing the
H3K9me3 and (B) 5mC probes. The split probes are shown in (C) and (D). The % cytotoxicity
was determined via an MTT assay. Error bars indicate the SD and n=3 biologically independent
repeats. * indicates statistically significant differences from a One-way ANOVA following a
post-hoc Tukey test.
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We also assessed the tumor forming potential of the sorted subpopulations of different
epigenetic modifications. Sorted cells were seeded onto Matrigel coated culture plates and tumor
formation potential was measured by calculating the area of the tumor spheroids, 2 weeks after
culture. The BiFC probes were employed for this assay due to the improved resolution offered by
the probes in drug resistance assays. Images of tumor spheroids obtained from various bins is
shown in Fig 4.4.5(A) and Fig 4.7.8. The corresponding histograms of tumor sizes are presented
in Fig 4.4.5(B). For both the H3K9me3 and 5mC probes, the higher modification levels
corresponded to smaller tumor sizes, indicating that there are innate differences in tumor formation
potential of MCF7 cells .
(A)

(B)

(C)

Figure 4.4.5: (A) Representative images of tumor spheroids formed on Matrigel coated surfaces
by different epigenetic bins. In (B) the histogram of tumor areas for the H3K9me3 split-probe is
presented and in (C), the same type of histogram produced by the 5mC probe sorting. Tumor size
is in pixel2. Scale bar = 25 µm.
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Conclusions
In this work, we developed a platform technology to analyze and to sort single cells based
on their epigenetic modification levels. cells can be analyzed using FACS and microscopy tools to
reveal their intrinsic heterogeneity in epigenetic modifications. The sorting capability developed
by our novel sensors allows us to unequivocally dissect epigenetic contributions to tumor growth
and development of drug resistance.
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Supporting Materials
4.7.1 Supporting table
Table 4.7.1: Amino acid sequences of various sensors used in this study showing the reader
domain of the probes that selectively recognize the epigenetic modifications H3K9me3 and DNA
methylation, respectively.
Protein

H3K9me3
probe

5mC probe

Amino acid sequences
10
ASQEFEVEAI
60
HDFNRRQTEK
110
RQDKNGNTQY
160
LTWTTTSRIF
10
MAEDWLDCPA
60
RYLGPACDLT
110
AGRSDTYYQS

20
VDKRQDKNGN
70
QKKLTWTTTS
120
LVRWKGYDKQ
170
SNNA
20
LGPGWKRREV
70
LFDFKQGILG
120
PTGDRIRSKV

30
TQYLVRWKGY
80
RIFSNNAGSG
130
DDTWEPEQHL

40
DKQDDTWEPE
90
GGGGSQFASQ
140
MNCEKCVHDF

50
QHLMNCEKCV
100
EFEVEAIVDK
150
NRRQTEKQKK

30
FRKSGATAGR
80
GGGFAEDWLD
130
ELTRYLGPAG

40
SDTYYQSPTG
90
SPALGPGWKR
140
DLTLFDFKQG

50
DRIRSKVELT
100
REVFRKSGAT
150
ILGGG
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4.7.2 Supporting method
4.7.2.1 Principal component analysis
PCA is a method of dimensionality reduction that generates a feature space where the principle
components are ordered by the amount of variance in the data captured. Image analysis generates
a large number of features, necessitating dimensionality reduction to visualize the data. Raw
images for feature extraction were obtained from a maximum intensity projection of a confocal
stack of probe or antibody channels. These images were analyzed using a customized Cell Profiler
pipeline to identify cell nuclei and measure the foci intensity, shape and texture. Measurements
were imported into the R programming language, version 3.4.0 under the IDE RStudio version
1.0.143. The base R function prcomp was used to scale and center the variables and run the PCA
algorithm. PCA was used to determine the significance of the differences between image features
from cells stained with the 5mC probe and cells stained with the antibody probe. In Fig. 4.7.2 (B) ,
the first and second principle components of the 5mC probe and the antibody overlap closely,
indicating that the image features from both sources are similar.
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4.7.3 Supporting figures

(A)

(B)

(C)

Figure 4.7.1: (A) Forward scatter height and area – FSC-H and FSC-A – are plotted against each
other to identify the regions of singlet cells and gate out the doublet events (B) Gating for live
cells based on previously gated singlet population (C) The autofluorescence background from
live cells was gated out to identify the GFP positive population
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(A)

(B)

Figure 4.7.2: (A) The Mander’s correlation coefficients, M1 and M2 for the H3K9me3 probe and
counterstained commercial H3K9me3 antibody are close to 1 indicating a high degree of positive
correlation. M1= 0.92 ± 0.1 and M2= 0.92 ± 0.1. The data is obtained from n=100 cells. (B)
Principal component analysis of the binding pattern of the 5mC probe and commercial 5mC
antibodies suggests that they are not statistically different from one another. In (C), additional
images of the probe and antibody are provided for comparison

91

(A)

(B)

Figure 4.7.3: (A) Bio-layer interferometry to determine the binding constants for the probes to
their target modifications. In (A), the H3K9me3 probe shows high selectivity for the H3K9me3
peptide as compared to the wild-type H3 histone. In (B), the dissociation constant of binding, Kd
is 0.162 ± 0.024 µM.
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(A)

(B)

Figure 4.7.4: (A) Additional images of cells treated with BIX01294 and transfected with
H3K9me3 probes (B) Additional images of cells treated with RG108 and transfected with 5mC
probes
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(A)

(B)

(C)

(D)

Figure 4.7.5: Top: Schematic of the control plasmid (NC) lacking an epigenetic reader domain.
(A) Intensity histograms of the negative control (NC) plasmid under increasing BIX01294
concentrations. The relative change in MFI of the GFP control plasmid upon drug treatment. The
data is plotted as MFI in (B). (C) Intensity histograms of NC under increasing RG108
concentrations with the MFI values shown in (D). The * represents a significant difference
(p<0.05) from the control untreated case from a One-way ANOVA test followed by post-hoc
Tukey’s test
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Figure 4.7.6: (A) Representative images of live cells transfected with the H3K9me3 and 5mC
probes obtained using confocal microscopy 24-hours post sorting. (B) Cell viability after sorting
in various populations.
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Figure 4.7.7: Cytotoxicity effects of Doxorubicin on MCF-7 cells. Data represents n=3
biologically independent repeats, error bars indicate standard deviation. The data was fitted to a
dose response model and the dashed lines indicate the fit. Dotted lines are indicative of the IC50
value.
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Figure 4.7.8: Additional representative images of tumors formed from sorted populations of Low,
medium and high H3K9me3 and 5mC levels respectively.
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5. IDENTIFYING DISTINCT HETEROCHROMATIN REGIONS USING
COMBINATORIAL EPIGENETIC PROBES IN LIVE CELLS

Abstract
The 3D spatial organization of the genome controls gene expression and cell functionality.
Heterochromatin (HC), which is the densely compacted and largely silenced part of the chromatin,
is the driver for the formation and maintenance of nuclear organization in the mammalian nucleus.
It is functionally divided into highly compact constitutive heterochromatin (cHC) and
transcriptionally poised facultative heterochromatin (fHC). Long regarded as a static structure, the
highly dynamic nature of the heterochromatin is being slowly understood and studied. These
changes in HC occur on various temporal scales during the cell cycle and differentiation processes.
Most methods that capture information about the heterochromatin are static techniques that cannot
provide a readout of how the HC organization evolves with time. The delineation of specific areas
such as fHC are also rendered difficult due to its diffuse nature and lack of specific features.
Another degree of complexity in characterizing changes in heterochromatin occurs due to the
heterogeneity in the HC organization of individual cells, necessitating single cell studies. Overall,
there is a need for live cell compatible tools that can stably track the heterochromatin as it
undergoes re-organization. In this work, we present an approach to track cHC and fHC based on
the signature epigenetic modifications associated with them. Unlike conventional immunostaining
approaches, we use small recombinant protein probes that allow us to dynamically monitor the HC
by binding to modifications specific to the cHC and fHC (H3K9me3, DNA methylation and
H3K27me3). We demonstrate the use of the probes to follow the changes in HC induced by drug
perturbations at the single cell level. We also use the probe sets combinatorically to simultaneously
highlight regions of cHC and fHC using a FRET based approach. Lastly, we compare the spatial
organization of HC in normal and cancer cells, where large instabilities have been observed in HC
organization.
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Introduction
The mammalian nucleus is functionally divided into several regions comprising primarily
of the chromatin, the nucleolus, and transcription factories. DNA is wrapped around histone
proteins to form the chromatin, which is arranged in a non-random fashion within the nucleus,
forming distinct chromosome territories183. Gene rich regions tend to be loosely compacted
(euchromatin or EC) and are commonly found near the center of the nucleus. Densely compacted,
largely gene poor regions184,185 (heterochromatin or HC) are most abundant near the nuclear
periphery. The 3D structure of chromatin has been extensively studied over past years.
Accumulating evidence suggests that the 3D spatial arrangement of chromatin largely encodes cell
functionality186,187, dictates inter- and intra- chromosomal interactions188, partially programs
transcription profile189 and thus ultimately determines the phenotype190. 3D chromatin structure is
thus largely conserved among similar eukaryotic cell types191. In healthy cells, euchromatin and
heterochromatin regions typically have well-defined boundaries which are essential for distinctive
gene activity and maintaining integrity during cellular processes192.
Euchromatin is typically less compact and thus does not have a well-defined structure,
while heterochromatin is highly compact and normally assumes a well-defined structure as
evidenced in literature163. Heterochromatin formation is the driving force behind the observed 3D
architecture of the genome and forms a basis for understanding the spatial organization within the
nucleus. The formation of heterochromatin occurs very early in development and is crucial for
differentiation193, as well as the establishment and maintenance of nuclear organization in
mammalian cells194,195. Repetitive DNA regions and developmentally regulated genes are the
major components of HC within the genome184. Functionally, heterochromatin may be divided
into two sub-classes184,196: 1) Constitutive heterochromatin (cHC) which is highly stable, heavily
compacted and gene poor, and, 2) Facultative heterochromatin (fHC) which tends to be less
compacted, developmentally regulated and transcriptionally poised. The functional distinction
between cHC and fHC is important because though both are transcriptionally silent, fHC retains
the potential to interconvert between cHC and EC. As a result of this flexibility, fHC may exist in
several distinct states (between the 11 nm and 30 nm chromatin fibers and other higher order states)
and thus modulate chromatin condensation197. cHC on the other hand is associated with higher
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order chromatin structures (>30nm) and is stably maintained at the pericentromeric and perinuclear
regions198.
Both the cHC and fHC modulate chromatin in order to maintain nuclear stability and
prevent the access of transcriptional machinery to repetitive DNA elements, curtailing their
transcription and recombination. The boundaries and spatial organization of both the cHC and fHC
have to be maintained199,200 in order to perform these functions. Overall, disruptions in the cHC
and fHC result in genomic instability201,202, transcription of transposable elements and silenced
repeats203 and loss of genomic organization. For instance, in diseases linked to repeat length
alterations, heterochromatin spreading can occur, leading to a loss of transcriptional elongation.
Such changes in heterochromatin composition are seen in heritable diseases such as Freidrich’s
Ataxia, Huntington’s disease and the Fragile X Syndrome204. Heterochromatin de-condensation is
commonly seen in cancer cells, such as in breast and ovarian cancer where the inactive X
chromosome is de-compacted leading to the expression of X linked genes205. Other widespread
changes in heterochromatin features, such as the hypomethylation and overexpression of
pericentric and satellite repeat elements are seen in cancer cells206,207. The dramatic loss of
heterochromatin at the nuclear periphery, leading to poor staining in malignant cancer cells, has
long been used as a maker by pathologists to identify specific cancers208. The destabilization of
HC and subsequent epigenomic instability is, however, an understudied issue in cancer biology.
The functional importance of cHC and fHC thus warrants careful examination of these
regions in the context of their relative positions within the nucleus. The distinction between cHC
and fHC is difficult to accomplish by conventional cytological stains196. Delineating these two
areas is of key importance in processes where the heterochromatin is disrupted.
HC is typically identified in single cells via the simple stains that bind to DNA. These
include 4’6-Diamidino-2-phenylindole (DAPI) for fixed cells and Hoechst 33342 for live cells,
which primarily bind to AT-rich heterochromatin regions, thus differentiating it from the
euchromatin regions of lower DNA density. Other approaches to identify heterochromatin are
banding and FISH209,210. which rely on the tightly compacted nature of heterochromatin DNA, or
the use of specific DNA sequences, respectively, to identify heterochromatin regions. The
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distinction between fHC and cHC, however, has been difficult to accomplish without the use of
antibodies specific to epigenetic marks found at these regions211. For instance, the cHC is primarily
characterized by a high density of H3K9me3 and DNA methylation184 while the fHC is enriched
in H3K27me3196. However, antibody-based methods require a fixation step which is not conducive
to live cell applications.
In this work, we present an approach to monitor fHC and cHC regions based on epigenetic
readouts. The probes directly inform the spatial distribution and abundance of epigenetic
modifications and thus offer a convenient tool to reveal the contributions of HC to various
biological processes.

Materials and Methods
5.3.1 Construction and verification of the heterochromatin probes
To identify and quantify epigenetic modifications (H3K9me3, H3K27me3 and DNA
methylation (5mC), we have engineered protein probes based on a multimerization strategy as we
detailed in our previous work161 and literature111. Native epigenetic domains, specifically chromodomain of chromodomain Y protein (CDY), chromodomain of the Polycomb 2 domain (PC2) and
the methyl-binding domain (MBD) of the MBD1 protein were selected for H3K9me3 and
H3K27me3 and 5mC, respectively. These domains were selected based on their high affinity to
epigenetic marks as well as high selectivity111,120,162,212. Each probe contains two (di-) repeats of
reader domains fused to a fluorescent protein (i.e., mEGFP and mCherry) via a flexible linker
(G4S). The probes were cloned into a mammalian expression vector, PRK5, (Addgene (plasmid
number: 18696), Cambridge, MA) and transfected into cell nucleus. Comparison between monoand di- probes suggest that only dimeric probes exhibit a similar spatial pattern to commercial
antibodies (anti-H3K9me3, ab8898, + Goat-anti-rabbit, Alexa Fluor 568 , (Abcam, Cambridge,
MA), anti-H3K27me3, ab192985, + Goat-anti-rabbit, Alexa Fluor 568 , (Abcam, Cambridge,
MA)and anti-5mC, #61256 (Active motif, Carlsbad, CA) + Donkey-anti-mouse Alexa Fluor 647)
as shown previously, as well as in Fig 5.4.2(B). Larger number of tandem repeats (e.g., four repeats)
did not improve resolution of our probes and may create steric hindrance for target-binding as we
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shown in our previous work161. The amino acid sequences of all probes containing dimeric
recognition domains are shown in Table 5.7.1.
5.3.2 Mammalian cell culture and transfection
Two different cell lines were used in this study, namely Human embryonic kidney 293T
(HEK293T) and MCF7 cells. All cells were maintained following standard cell culture
protocols156. Live cell tracking were accomplished using 8 well µ-slides or grid slides (ibidi,
Fitchburg, WI) as we descried previously161.
Cells were exposed to various epigenetic drugs to perturb the intrinsic epigenetic
modification levels. Generally, for all drug exposure experiments, cells were exposed to the drug
when they attained a confluence of 40-50%. Specifically, BIX-01294 (Sigma, St.Loius, MO) a
histone methyltransferase (G9a HMTase) inhibitor157,158 was used to lower the H3K9me3 levels.
A DNMT1 inhibitor, RG108 was used to lower the DNA methylation level at CpG
dinucleotides159,160. DZNep which affects various histone methyltransferases was used to reduce
the levels of H3K27me3213.
5.3.3 Analysis of epigenetic modification levels
Global changes in epigenetic modifications were analyzed via commercial ELISA kits
(Total H3 ELISA, H3K9me3 ELISA, H3K27me3 ELISA and Global DNA methylation ELISA,
Active Motif (Carlsbad, CA)). Relative changes in epigenetic modification levels were determined
by comparing the modification level of our sample to an untreated control.
5.3.4 Immuno-fluorescence staining
Transfected cells were co-stained with commercial antibodies. Specifically, cells
transfected with the probes were fixed using methanol or 4% paraformaldehyde as a fixative
agent214. After a one-hour block with 1% BSA in PBS, cells were incubated with the respective
primary antibody for 1 hour at RT: rabbit Anti-Histone H3K9me3 antibody (ab8898, Abcam,
Cambridge, MA), rabbit Anti-Histone H3K27me3 antibody (39157, ab192985, Abcam,
Cambridge, MA) and mouse Anti 5-methylcytosine antibody (61480, Active Motif, Carlsbad, CA).
For the latter (5mC-antibody), an additional denaturing step was required between blocking and
incubation with 1˚ antibody since the 5mC-antibody binds only to single-stranded DNA. The
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denaturing step was carried out using 2N HCl and incubating for 30 minutes at RT followed by
3X PBS washes. Cells were then washed with 3X PBS and incubated for 1 hour at RT with the
secondary antibody: Goat-anti rabbit Alexa Fluor 568 (Abcam, Cambridge, MA) or Donkey-antimouse Alexa Fluor 647 (Millipore, Billerica, MA). Coverslips were washed with 3X PBS and
mounted using glycerol on slides for imaging. DNA staining was performed using Hoechst (Sigma,
St Louis, MO) stain at a 1:500 dilution and staining for 10 minutes.
5.3.5 Image acquisition and analysis
Live or fixed cells were imaged on a Nikon Eclipse Ti-E microscope equipped with a 60X
oil immersion objective lens. 20-30 X-Y optical sections were imaged to collect Z-stack images.
GFP and mCherry were excited using a 488nm and 534 nm laser excitation source, respectively.
For experiments involving colocalization of different probes, two laser lines were used in a
sequential mode to avoid bleed-through effects. The confocal pinhole was set to S (small) and low
laser intensities were used to avoid photo-bleaching effects.
Images for sensitized FRET measurements were acquired in a sequential manner in the
GFP, mCherry and FRET channels at RT. The filter sets employed were Donor/GFP (Excitation:
488/2nm, Emission: FITC), Acceptor/mCherry (Excitation: 532/2 nm, Emission: Cy5) and FRET
(Excitation: 488/2 nm, Emission: Cy5). To determine the spectral bleed-through of GFP into the
FRET channel, a donor-only sample was imaged using Donor/GFP and FRET settings. Direct
excitation of the acceptor was calculated by imaging an acceptor-only sample in the
Acceptor/mCherry and FRET channels. Donor- and acceptor-emission of each sample was also
determined and used as a factor to normalize FRET signal and thus correcting for variations in
protein expression levels across cells.
Co-localization analysis was performed using the ImageJ plugin JACoP. Thresholding was
performed using Costes method215 to calculate the Mander’s coefficients. FRET analysis was
performed using the ImageJ plugin PixFRET216. All other images were analyzed via CellProfiler
using a customized pipeline (available upon request).

103
5.3.6 Statistics
All statistical analysis and error propagation calculations were performed using Graphpad
Prism by a one-way ANOVA analysis followed by post-ANOVA testing using Tukey’s test,
considering p < 0.05 to be statistically significant. Origin Pro and Graphpad Prism were both used
for creating figures and graphs. A minimum of 100 cells was analyzed for calculating the
colocalization coefficients and volume fractions. ELISA was performed on a minimum of three
biological independent samples with > 2 technical repeats of each. FRET analysis was performed
for n > 30 cells.

Results and Discussion
5.4.1 Quantifying Constitutive Heterochromatin (cHC) levels
As our previous work has demonstrated, the MBD1 domain and the CDY1 domain can be
engineered to probe the DNA methylation and H3K9me3 levels in a flow cytometry assay. FACS
provides rapid sorting and single cell measurements, but is very limited in elucidating the
molecular distribution within the nucleus33. A microscopy-based approach can thus be very useful
in examining the spatial distribution of heterochromatin associated modifications within the cell
and. We tested the H3K9me3 and 5mC probes in HEK293T cells (live cell images in Fig. 5.7.1,
probe schematic in Fig. 5.4.1(A)) and observed the characteristic cHC distribution. The H3K9me3
probe is localized at the nuclear periphery217 and around the peri-nucleolar regions forming distinct
ring-like structures around the nucleolus218–220. The 5mC probe shows a pattern of small punctate
dots, corresponding to dense regions of DNA methylation111,164.
Quantification of cHC was performed by perturbing the system by the addition of
epigenetic drugs and measuring the changes in cHC levels using the H3K9me3 and 5mC probes.
BIX-01294 (Sigma, St.Loius, MO) a histone methyltransferase (G9a HMTase) inhibitor157,158 was
used to lower the H3K9me3 levels. The drug concentrations chosen for BIX-01294 treatment were
3 and 5 µM respectively in order to minimize toxicity effects and morphological changes in cells157.
At the specified [BIX01294], there is a significant drop in the H3K9me3 levels measured by the
total volume occupied by the probe in the nucleus and the mean foci intensity per nuclei (Volume
fraction and FIPN respectively in Fig. 5.4.1(B)) which closely matches the values obtained using
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a commercial ELISA kit. Visualizing the changes induced by BIX01294, in Fig. 5.4.1(B), top
panel, fewer foci of H3K9me3 and lesser modification levels at the nuclear periphery are visible.
As shown in Fig. 5.4.1(B), the drop in the volume fraction occupied by bound probes is ~ 28%
and 74% of the original value at [BIX01294] = 3 and 5 µM. The drop in modification levels, is
significantly different with p<0.05 as compared to the control sample. The H3K9me3 probe is also
able to resolve the differences in H3K9me3 levels at two different drug concentrations. Similarly,
the volume fraction occupied by the 5mC probe drops significantly as the methylation levels are
lowered by the DNMT inhibitor RG108 (Fig. 5.4.1(C)). As the number and intensity of the foci
decrease, the volume fraction drops to ~75% and 55% of the original value (statistically significant
with a p<0.05). These numbers are in agreement with the ELISA values quantifying the relative
DNA methylation levels.
To assess the spatial resolution offered by the probes, we compared the binding pattern
with commonly used live cell dyes for staining cHC. The Hoechst dye is a non-specific DNA
binding agent that is routinely used to stain nuclei and heterochromatin in live and fixed cells221.
In Fig. 5.4.1(D) (top panel), cells expressing the H3K9me3 probe were counterstained with
Hoechst to compare the features delineated by both methods. The overlap between the H3K9me3
probe signal and the Hoechst dye are presented in the merge channel and show an almost perfect
overlap. However, upon zooming into certain regions of interest, the probe offers higher spatial
resolution as compared to the non-specific DNA stain. A pixel plot analysis of typical cHC regions
at the peri-nucleolus and the nuclear periphery (see Region 1&2, Fig. 5.4.1(D)), show that a
diffuse signal in obtained by the Hoecsht dye and sharply defined peaks are obtained in the
H3K9me3 probe channel The specificity of the probe for H3K9me3 leads to a higher signal:noise
ratio for as compared to the diffuse and poorly resolved signal obtained in the Hoechst channel.
The results obtained with our 5mC probe closely mirrors the H3K9me3 probe. There is significant
overlap between the 5mC probe and the Hoechst signal which binds non-specifically to DNA
primarily at heterochromatin locations. Since the heterochromatin is enriched in DNA, this dye
even acts as an indirect measure of DNA methylation and has been used to validate MBD1 probes
in previous works111,164.
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Figure 5.4.1 A) Schematic of the Heterochromatin recognition probes. B) Top panel: Maximum
intensity projections of the 3D confocal stacks of the cells expressing the H3K9me3 probes and
treated with increasing concentrations of BIX01294. Bottom panel: Corresponding decrease in
relative H3K9me3 levels upon drug treatment as captured by ELISA and volumetric analysis. C)
Top panel: Maximum intensity projections of the 3D confocal stacks of the cells expressing the
5mC probes and treated with increasing concentrations of RG108. Bottom panel: Corresponding
decrease in relative 5mC levels upon drug treatment. Scale bar = 10 µm. * indicates a
statistically significant difference with p<0.05, n= 100 for volumetric analysis and 3 for ELISA.
Error bars represent the standard deviation. D and E) Co-stained images of cells expressing the
H3K9me3 or 5mC probe with a DNA dye (Hoechst). Significant heterochromatin regions are
highlighted in regions 1 and 2 of both cells to demonstrate the improved spatial resolution
offered by both probes. Scale bar = 10 µm in top panel and 2 µm in zoomed in regions of the
bottom panel.
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However, the resolution offered by MBD1 based 5mC probes is much greater than the
Hoechst dye as can be seen in zoomed in Regions 1 and 2 of the cell in Fig. 5.4.1(E), showing
sharp peaks of DNA methylation islands. Moreover, since commercially available DNA
methylation antibodies bind only to single stranded DNA, they require an additional HCl
denaturing step for binding. The non-toxic and live cell compatible feature of the 5mC probe,
coupled with its improved resolution make it an attractive alternative to assess DNA methylation
levels.
5.4.2 Quantifying facultative heterochromatin levels
The success of both the H3K9me3 and 5mC probes in capturing regions of cHC lead us to
examine modifications associated commonly with the facultative heterochromatin (fHC). The fHC
is also transcriptionally silent but remains poised to convert to euchromatin (euchromatin) under
temporal or spatial control (such as during development or cell-cycle stages or changes in 3 D
nuclear reorganization)196. Interestingly, since the fHC occupies an intermediate state between
cHC and EC, it is often indistinguishable from both by conventional staining methods. The
epigenetic signatures of the fHC are however quite distinctly different from cHC and EC. The
epigenetic modification H3K27me3 often in tandem with DNA methylation is enriched at various
fHC locations such as the inactive X chromosome (Xi)222, autosomally imprinted genomic loci223
and HOX gene clusters224.
We developed a H3K27me3 probe that could capture dynamic changes in this modification
level. The PC2 domain was used as the epigenetic reader domain that binds to H3K27me3 sites225.
Images of HEK293T cells expressing the probe are shown in Fig. 5.4.2(A) (top panel). The signal
is more diffused as compared to the denser H3K9me3 and 5mC modifications, but the probe is
successful in capturing features of H3K27me3 distribution. This includes foci of H3K27me3 and
dense regions such at the inactive X chromosome which is generally present near the nuclear
periphery. The pattern obtained by the H3K27me3 probe exactly matches that of commercial
antibodies (see Fig. 5.4.2(A), bottom panel). We quantified the extent of overlap between the
probes and the antibody in Fig. 5.4.2(B), obtaining a Mander’s correlation coefficient close to 1,
indicating a high degree of positive pixel-by-pixel correlation between the two channels (probe
and antibody).
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The quantitative ability of the probes to capture changes in H3K27me3 levels was
determined using the volumetric approach described above. The drug 3-deazaneplanocin A
(DZNep) which inhibits multiple histone methyltransferases was used to selectively lower the
H3K27me3 levels at a concentration of 0-5 µM226. Images of cells exposed to the drug at varying
concentrations are shown in the top panel of Fig. 5.4.2(C). The signal is extremely diffuse at
increasing drug concentrations with most observable foci being lost (additional images are
provided in Fig. 5.7.3). The corresponding drop in H3K27me3 levels was assessed using a
commercial ELISA based approach (Fig. 5.4.2(C), bottom panel) showing a significant decrease
in the H3K27me3 levels. The volume fractions occupied by the H3K27me3 probe drops to ~40%
and 25% of the original value at 3 and 5 µM DZNep concentrations which closely matches the
relative values obtained by ELISA. These differences are statistically significant in both cases as
compared to the control untreated samples (p<0.001).
The spatial resolution offered by the H3K27me3 in delineating the fHC is significantly
better when compared to the Hoechst staining. At the nuclear periphery (region 1) and the
perinucleolar areas (region 2) for the cell shown in Fig. 5.4.2(D), the peaks obtained using the
probe are sharply defined as compared to the Hoechst signal. Since the Hoechst dye does not
differentiate between the cHC and fHC, the H3K27me3 probe offers an added advantage in
capturing specific features of the heterochromatin.
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Figure 5.4.2: (A) Live cell images of HEK293T cells expressing the H3K27me3 probe (top
panel). The cells were counterstained with a commercially obtained antibody against H3K27me3
and shows significant overlap. (B) The Mander’s correlation coefficients for the signal obtained
in the probe and antibody channels. (C) Top panel: Images of cells treated with the drug DZNep.
Bottom panel: corresponding changes in H3K27me3 measured by volume fraction and ELISA.
Scale bars = 10 µm. * indicates a statistically significant difference with p<0.05, n= 100 for
volumetric analysis and 3 for ELISA. Error bars represent the standard deviation. (D) The probe
was co-stained with Hoechst dye to demonstrate the improvement in signal:noise obtained by
using a probe specific to the H3K27me3 modification.
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5.4.3 Single cell dynamic trajectories of heterochromatin levels
The main goal of this work was to develop specific probes for the monitoring of cHC and
fHC as they undergo dynamic changes at the single cell level. The H3K9me3, 5mC and
H3K27me3 probes selectively identify the cHC and fHC and may thus be used in combination to
assay both regions simultaneously. We demonstrated the use of the probes in live cell tracking, by
introducing an alternative fluorescent tag (mcherry) on the probes for tracking two modifications
simultaneously. Drug perturbations were performed to modulate the epigenetic landscape of the
chromatin. We then tracked these dynamic changes by following individual cells as they
underwent normal cellular processes in the presence and absence of epigenetic drugs.
Since the cHC has well-defined features and forms the more static part of heterochromatin,
we began by monitoring dense regions of cHC identified by a high density of H3K9me3 and 5mC.
The H3K9me3 and 5mC probes were simultaneously introduced into HEK293T cells to monitor
changes in cHC as cells undergo growth and division. As can be seen in Fig. 5.4.3(A), at T=0 hrs,
the nuclei exhibit the characteristic pattern of binding corresponding to H3K9me3 and 5mC
distribution with a defined nuclear ring and islands of H3K9me3 and DNA methylation. The
patterns overlap significantly with each other, as expected, since both probes are highly specific
to cHC. The binding pattern is retained in daughter cells upon successive cell divisions.
We then perturbed the system by adding a combination of drugs that affects both
modification levels (BIX01294 and RG108 at 5 µM and 100 µM respectively) and monitored the
variations in the cHC with time. Images obtained from dynamic tracking are presented in Fig.
5.4.3(B). As early as T= 12hrs post drug addition, a decline in both H3K9me3 and 5mC is seen.
The intensity of binding at the nuclear periphery decreases and the number of bright foci also
decreases. For the 5mC probe, we observed smaller, dimmer foci along with the accumulation of
unbound probes in the nucleolus as sites of 5mC are lost. These changes are more pronounced with
time, resulting in a lower fluorescent intensity per nuclei (quantified in Fig. 5.4.3(E), for additional
single cell images and grid slide coordinates, see Fig 5.7.3(A)). The cumulative effect of adding
multiple epigenetic drugs can be decoupled by studying the effects of a single drug on either
H3K9me3 or 5mC levels (data for individual drug treatments presented as dashed lines in Fig
5.4.3(E), cell images in Fig 5.4.4(A) and (B)). Firstly, the addition of RG108 appears to increase
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the H3K9me3 modifications in the early stages of drug exposure. This increase is maintained at T
= 24hrs and eventually approaches the same level as the untreated case (at T = 48hrs). The addition
of BIX01294 modulates the H3K9me3 level as expected with steady losses seen at increasing time
points. In a combinatorial effect of RG108 and BIX01294 on H3K9me3 levels, it appears that the
declining effects of BIX01294 addition are offset by the increase in H3K9me3 levels induced by
RG108. In examining the effect of BIX01294 on DNA methylation, a decrease in 5mC levels
occurs when the cells are exposed to BIX01294. Both BIX01294 and RG108 successively lower
the 5mC level with time and the cumulative effect of both drugs is slightly more pronounced than
individual treatments (Fig 5.4.3(E), bottom panel).
There are several possible regulatory pathways that might contribute to the crosstalk
observed in these experiments. For instance, the H3K9me3 mark recruits HP1227 and UHRF1228,229,
both of which have regulatory links with DNA methyltransferases. In HMT knockout MESC, a
depletion of DNMT is observed at the pericentromeric heterochromatin, though a similar decrease
in H3K9me3 levels is not observed in DNMT knockout cells227. It is thus possible that a decrease
in H3K9me3 induced by BIX01294 can lead to a decrease in DNA methylation levels as well.
Readers of methylation marks, such as MeCP2 are present along with H3K9me3 at cHC and
interact with HMT’s, but the loss of these readers may not necessarily decrease the H3K9me3
levels230.
After developing an understanding of how the cHC landscape might be altered with drug
perturbations, we examined the fHC which is less organized and spatially distinct from the cHC.
Our goal was to distinguish these two areas from each other and monitor their potential overlap as
chromatin landscape is perturbed. Since DNA methylation and H3K27me3 are both associated
with the fHC, we chose to use the H3K9me3 and H3K27me3 probes together since these
modifications are usually spatially distinct231 with evidence of cross-talk at selective gene loci232.
We monitored simultaneous changes in cHC and fHC as cells undergo growth and division (see
Fig 3C and D).
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Figure 5.4.3: (A) HEK293T cells were transfected with the H3K9me3 and 5mC probes and
imaged at successive time points. The cells undergo division and the daughter cells express both
probes with distinctive patterns of heterochromatin. In (B), the same probe sets are introduced in
cells exposed to RG108 and BIX01294 which lower the histone methylation levels (arrow
indicates the time of addition of the drug). The pattern is lost over time as the drug decreases the
binding sites available for the probes. In (C) and (D), the probe combination tested is H3K9me3
and DNA methylation with or without the addition of BIX01294 and DZNep. In (E) and (F), the
mean foci intensity at various time points is captured for both cases along with the data for
individual drug exposures (shown in dotted lines). The * indicates statistically significant
differences (p<0.05) from the untreated case, following a One-Way ANOVA, Tukey’s post hoc,
n= 30 cells.
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As the cell pictured at T= 0 hrs in Fig 3C at undergoes division (at T =12 hrs), the
H3K27me3 modification is associated with the chromosomes and also expressed in the daughter
cells. The pattern of binding seen with the H3K27me3 probe in Fig 2A is retained upon cell
division. Similarly, the H3K9me3 probe is associated with the nuclear periphery and shows the
characteristic pattern of cHC. The daughter cells retain this pattern upon division. There is little to
no overlap between the probes as is expected with these two modifications232. The change in mean
foci intensity with time is presented in Fig. 5.4.3(F) where the signal obtained by both probes is
steady with some decline at the last time point.
cHC and fHC were then perturbed by the addition DZNep and BIX01294 both at final
concentrations of 5 µM (see Fig. 5.4.3(B)). Immediately following drug addition (at the 12 hr time
point), the cumulative effect of the drugs on both modifications is a loss in the signal. This change
is more prominent at increasing time points with the signal becoming more diffuse as H3K9me3
and H3K27me3 levels decrease. Data from single drug exposure for each probe (see dashed lines
in Fig 5.4.3(F) and cell images in Fig 5.7.4(C) and (D)) provide some understanding of the
observed effects. The addition of DZNep counters the slight increase in H3K9me3 levels seen in
the untreated case (at T = 0 hrs). The modification level remains steady at increasing exposure
times and is similar to the untreated case at T = 48 hrs. The overall effect of adding BIX01294 and
DZNep is a lowering of the H3K9me3 level that is very similar to the effects of adding BIX01294
alone. The addition of BIX01294 interestingly increases the H3K27me3 levels 12 hours after
exposure, though this trend is not maintained over successive time points. The addition of DZNep
causes a sharp decline in the H3K27me3 levels. The cumulative effects of adding two drugs is not
entirely an additive effect of individual drugs (at T-12hrs), indicating that synergistic mechanisms
might be at work. The loss of HMT’s and subsequent loss of H3K9me3 can lead to a redistribution
of H3K27me3 in mouse cells220 or a gain of H3K27me3 in fungi233. Additional single cell images
for both treated and untreated cases along with the phase contrast images of the grid slide
coordinates is presented in Fig. 5.7.3(B).
Finally, dynamic trajectories of single cells can be obtained by following an individual cell
as it undergoes division. This can be done by quantifying the mean foci intensities of the original
and divided populations. The data for single cell modulation of epigenetic levels upon
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combinatorial drug exposure is presented in Fig 5.7.5. 5 individual cells are presented for each of
the probe sets.
5.4.4 Heterochromatin regions identified by FRET
Techniques available for the detection of histone PTMs and DNA methylation are presently
limited to detecting single modifications. Some tool sets relying on multivalent domains or
bimolecular fluorescence complementation (BiFC) have been developed for the detection of
bivalent chromatin and epigenetic modifications at repetitive regions of the genome171. However,
there are some limitations to these tools, namely the signal-to-noise ratio and localization of
multivalent sensors234 and the irreversible signal generated by BiFC probes169. An alternate FRET
based approach is offered by the probes developed in this study to visualize epigenetic
modifications that co-exist on the nucleosome level (schematic presented in Fig. 5.4.4(A)). The
mEGFP and mCherry fluorescent moieties form a well-established FRET pair235,236 and can be
used for the simultaneous visualization of two epigenetic modifications.
We first demonstrated the feasibility of using the fluorescent probes as a FRET pair by
constructing a FRET positive control plasmid consisting of an mEGFP fluorophore connected by
a flexible linker to an mCherry fluorophore, driven by the same CMV promoter present in the
probes and containing an NLS signal (See Fig. 5.7.6(A) for a schematic). A strong FRET
interaction is expected between the pair since the short flexible linker allows for free rotation. A
negative control (See Fig. 5.7.6(A)) consisting of an mEGFP only and an mCherry only plasmid
co-transfected together was used. In the latter case, no FRET is expected since the two
fluorophores will be freely diffusing in the nucleus and will not be within the narrow nanometer
range in which FRET interactions are expected to occur. The Positive and Negative FRET control
samples were imaged with the appropriate donor only and acceptor only controls as described
earlier. The absolute and normalized FRET values are shown in Fig. 5.7.6(B) for two
representative single cells expressing the controls.
Having established that quantifiable FRET interactions occur between the two
fluorophores, we assessed the possibility of obtaining FRET measurements from the probe sets. It
is expected that for the GFP and cherry tagged versions of the same probe, a positive FRET
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interaction should occur since the probes bind at the same target site and should thus be in close
proximity to each other. We used the H3K9me3 probe to demonstrate the occurrence of FRET
when the H3K9me3 probe binds at the sites of histone methylation. As shown in Fig. 5.4.4(B) and
5.7.7(A), the NFRET values indicate that FRET occurs when the probes bind at identical locations.
A negative control in this case is a probe that binds at regions of euchromatin where H3K9me3 is
not expected to occur. We used a probe that binds to H3K14ac, a well-established euchromatin
mark, developed by us previously161. In Fig. 5.7.7(B), the H3K14ac probe and H3K9me3 probe
do not co-localize well or have any discernable FRET interactions.
We employed the cHC and fHC probe sets to delineate regions where quantifiable FRET
interactions occur. We first looked at a probe set which we expect will generate a strong FRET
signal due to the density of modifications present. FRET between the 5mC probe and H3K9me3
probe is presented in Fig. 5.5.4(B). While the signal is weaker than the H3K9me3-H3K9me3 probe
combination, there is a significant NFRET value after accounting for expression level
normalization. The relative NFRET value of the H3K9me3-5mC combination is 70% of the
H3K9me3-H3K9me3 pair (see Fig. 5.4.4(C)). Distinct features of the cHC are observed in the
FRET channel and FRET Index images (Panel 2, Fig 5.5.4(B)). Foci are highlighted at the nuclear
periphery and at the heterochromatin surrounding the nucleolus. The overall background is
reduced since FRET interactions occur only at regions where both modifications are present
simultaneously.
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Figure 5.4.4: A) Schematic showing the FRET interactions occurring between two probes under
various conditions positive FRET when (i) both modifications present and no FRET when (ii) no
modifications or (iii) and (iv) single modifications are present. B) FRET occurring between the
various probe sets. The FRET index is an absolute FRET value whereas the NFRET is
normalized by taking the donor and acceptor expression levels into account. In C), the relative
NFRET between different probe sets is quantified.

Similarly, the FRET obtained from the H3K9me3-H3K27me3 and 5mC-H3K27me3, i.e.
FRET at fHC and cHC locations shows that the H3K9me3-H3K27me3 interaction is the extremely
weak since these probes are largely mutually exclusive but are known to interact in certain genomic
contexts such as telomeres237, bivalent promoters238,239 and the inactive X chromosome240. The
relative NFRET for 5mC-H3K27me3 is lower the H3K9me3-5mC combination and is about 50%
of the NFRET of the H3K9me3-H3K9me3 pair. This is expected since DNA methylation and
H3K27me3 frequently occur together at the inactive X chromosome and autosomally imprinted
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loci196. Bright areas of colocalizaed modifications can be seen in the FRET and FRET index
channels (Fig 4B, third panel).
5.4.5 Comparison of heterochromatin regions in normal and cancerous cells
Heterochromatin instability is a hallmark of a large number of cancers with significant
changes in the higher order chromatin structure and loss of the heterochromatin Barr body
identified in cancer241,242. Expected losses of heterochromatin are at the repetitive regions of
pericentromeric HC and at the inactive X chromosomes among others205. We tested the
applicability of our probes in evaluating heterochromatin organization of a breast cancer cell
line, MCF7. The results from the introduction of our cHC and fHC probes are shown in Fig.
5.4.5. Firstly, using the H3K9me3 probes, we observed a reduction in the probe intensity at the
nuclear periphery, a feature that was quite prominent in HEK293T cells. We also observed fewer
islands of H3K9me3, mostly clustered towards the center of the nucleus (Panel 1 and 2, Fig.
5.4.5). The DNA methylation foci are also evidently reduced in this cell line. For the H3K27me3
probe, distinct features were observed, such as the intensity at the nuclear periphery and around
the nucleolus. In evaluating the interaction between the probes, we observed that the FRET
interactions between the H3K9me3-H3K9me3 positive control was still the highest. The probe
pairs H3K9me3-5mC and H3K27me3-5mC demonstrated similar NFRET values. There was
almost no interaction between the H3K9me3-H3K27me3 probes. Additional spatial
quantification methods are required to better differentiate the heterochromatin in normal and
cancer cell lines using the probes.
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Figure 5.4.5: (A) The probes were expressed in a cancer cell line, MCF7 and the pattern of
epigenetic modification was examined through FRET interactions. In (B), the relative NFRET
values are presented.

Conclusions
We developed an epigenetic platform for identifying cHC and fHC compartments of the
HC. The probes are compatible with live cell applications and allowed us to monitor changes in
the chromatin landscape over a time scale of days. The use of probes in combination provides a
simultaneous readout of both cHC and fHC and FRET interactions between the probes help in
identifying areas where bivalent chromatin may occur. The altered chromatin landscape in cancer
cells can be mapped using the probes in combination as our results have demonstrated.
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Supporting Materials
5.7.1 Supporting table
Table 5.7.1: Amino acid sequences of the active epigenetic domains of all constructs used in this
study.
Protein
Monomeric
CDY1

Dimeric
CDY1

Monomeric
MBD1

Dimeric
MBD1

Monomeric
PC2

Dimeric
PC2

Amino acid sequences
10
ASQEFEVEAI
60

20
VDKRQDKNGN
70

30
TQYLVRWKGY
80

HDFNRRQTEK
10
ASQEFEVEAI
60
HDFNRRQTEK
110
RQDKNGNTQY
160
LTWTTTSRIF
10
MAEDWLDCPA

QKKLTWTTTS
20
VDKRQDKNGN
70
QKKLTWTTTS
120
LVRWKGYDKQ
170
SNNA
20
LGPGWKRREV

RIFSNNA

60
RYLGPACDLT
10
MAEDWLDCPA
60
RYLGPACDLT
110
AGRSDTYYQS
10
FPVDLVYAAE
60
DIYEQTNKGS
10
FPVDLVYAAE
60
DIYEQTNKGS
110
YNTWEPEVNI

70
LFDFKQGILG
20
LGPGWKRREV
70
LFDFKQGILG
120
PTGDRIRSKV
20
KIIQKRVKKG
70
GGGGGS
20
KIIQKRVKKG
70
GGGGGSFPVD

120
LDRRLIDIYE

40
DKQDDTWEPE

50
QHLMNCEKCV

30
TQYLVRWKGY
80
RIFSNNAGSG
130
DDTWEPEQHL

40
DKQDDTWEPE
90
GGGGSQFASQ
140
MNCEKCVHDF

50
QHLMNCEKCV
100
EFEVEAIVDK
150
NRRQTEKQKK

30
FRKSGATAGR

40
SDTYYQSPTG

50
DRIRSKVELT

30
FRKSGATAGR
80
GGGFAEDWLD
130
ELTRYLGPAG
30
VVEYRVKWKG

40
SDTYYQSPTG
90
SPALGPGWKR
140
DLTLFDFKQG
40
WNQRYNTWEP

50
DRIRSKVELT
100
REVFRKSGAT
150
ILGGG
50
EVNILDRRLI

30
VVEYRVKWKG
80
LVYAAEKIIQ
130
QTNKGS

40
WNQRYNTWEP
90
KRVKKGVVEY

50
EVNILDRRLI
100

80
GGG

RVKWKGWNQR

121
5.7.2 Supporting figures

Figure 5.7.1: Representative live cell images of live HEK293T cells expressing the various
heterochromatin probes used in this study. The scale bar is equivalent to 10 µm.
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Figure 5.7.2: Maximum intensity projections of 3D confocal stacks of HEK293T cells expressing
the H3K27me3 probe and exposed to varying concentrations of the drug DZNep. The scale bar is
equivalent to 10 µm.
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Figure 5.7.3: (A) Time series of HEK293T cells simultaneously expressing the H3K9me3 and
H3K27me3 probes, imaged over 48 hours at 12-hour intervals. The top panel shows the merged
channels at successive time intervals to demonstrate that the same area is imaged repeatedly. The
scale bar = 50 µm. The bottom panel is a zoomed in view of a single cell expressing both probes
as it continues to grow and divide (scale = 10 µm). The probes show distinctive patterns of
H3K9me3 and 5mC. In (B), cells exposed to RG108 and BIX01294 at 5 µM concentration each
are followed similarly. Arrow indicates the time of drug addition. The distinct pattern of
modifications is lost over time. (C) Cells expressing the H3K9me3 and H3K27me3 probes are
tracked over successive time points. In (D) the cells expressing both probes are exposed to
BIX01294 and DZNep

124

(A)

(C)

(B)

(D)

Figure 5.7.4: (A) Time series of HEK293T cells simultaneously expressing the H3K9me3 and
5mC probes, imaged over 48 hours at 12-hour intervals. A single drug BIX01294 was added to
the cells to evaluate its effect on the epigenetic modifications. In (B), the same combination of
probes is tested with RG108. Arrow indicates the time of drug addition. (C) H3K9me3 and
H3K27me3 probes tested with BIX10294. In (D) the cells expressing both probes are exposed to
DZNep
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Figure 5.7.5: Time trajectories of response to drug exposure for individual cells expressing specific
probes
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(A)

(B)

Figure 5.7.6: (A) Schematic of the FRET control plasmids used in this study. The positive FRET
control is a mEGFP-mCherry fusion connected by a flexible linker and containing an NLS, but
no epigenetic domain. The negative controls are individual plasmids that are not connected and
hence will not be spatially close for FRET to occur. In B) the various detection channels are
shown with the first two being the donor and acceptor channels the third being the FRET
channel. The FRET panel shows the absolute FRET which is very high for this positive control.
In the NFRET panel, a normalization is performed based on the expression levels of both
plasmids. For the negative FRET case, there is no signal in the FRET and NFRET channel or in
the third panel after accounting for bleed-through corrections.
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A

B

Figure 5.7.7: A) The positive FRET control involves the use of the same probe tagged with the
FRET fluorophore pair. The H3K9me3 probe tagged with mEGFP and mCherry was used for
transfection and the NFRET values are presented in the right panel. B) A negative control
involving the H3K9me3 probe and a previously developed H3K14ac probe is expected to bind in
different locations, no signal is obtained in the FRET or NFRET channels since these
modifications do not colocalize. Scale bar = 10 µm.
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A

B

Figure 5.7.8: A) Additional FRET images for various probe combinations. Scale bar = 10 µm.
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6. SUMMARY AND FUTURE WORK

Summary
In summarizing this work, we have developed a framework for understanding the
contributions of epigenetics to tumor heterogeneity. In the first part of this thesis, we studied the
impact of epigenetic modifications and their readers on modulating chromatin architecture. In the
second part of this thesis, we focused on developing cross-platform tools to better characterize the
epigenetic background associated with tumor heterogeneity. Towards the conclusion of this thesis,
we have managed to (i) elucidate the role of a poorly understood epigenetic modification (5hmC)
in modulating chromatin structure (ii) developed a live cell compatible FACS platform for sorting
cells based on their epigenetic content (iii) simultaneously monitor cHC and fHC of
heterochromatin dynamically in live cells. A mechanistic understanding or technical capability
was previously lacking all three cases, to the best of our knowledge. Overall, this work contributes
to the fields of biology, medicine and engineering by providing an expandable library of tools that
can be used to characterize epigenetic modifications in tumor heterogeneity and development of
drug resistance.

Future work
There are several interesting technical and scientific avenues that can be pursued using the
probes developed in this work.
Two technical advancements to both platforms that present themselves are (i) rapid FRET
detection on a FACS platform and (ii) super-resolution imaging for an intricate molecular picture
of heterochromatin organization. The motivation behind the first goal is the alteration of multiple
epigenetic modifications in ITH with frequent cross-talk between modifications. The rapid
detection of co-localized modifications can be accomplished by using FRET interactions between
them, detectable on a FACS platform. FACS-FRET or FCET has been successfully used to
quantify protein-protein interactions since it is a non-invasive and high-throughput and
quantitative method243–245. With some optimization and suitable controls, our initial results show
that the H3K9me3 and 5mC probes can be used to detect FRET interactions on a FACS platform.
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Future efforts can be geared towards quantifying the extent of interactions with various probe
combinations in multiple cell lines. Our second goal is motivated by the promising spatial
resolution offered by the probes in assessing changes in the heterochromatin composition.
Detecting these changes at the level of the 30nm chromatin fiber would be an invaluable tool in
furthering our understanding of dynamic heterochromatin. Attempts have already been made to
determine the chromatin folding and spatial organization using DNA dyes and antibodies to
epigenetic modifications in fixed cells211,246. Using our live-cell compatible probes for superresolution applications necessitates the use of alternate labeling strategies that are compatible with
super-resolution imaging, such as Halo tag247 and mEOS248 tag.
The changes in epigenetic modifications impacting tumor heterogeneity are studied here
from an exclusively global perspective. However, locus specific changes in epigenetic
modifications are widely observed in cancer, with repetitive DNA being hypomethylated249 and
tumor suppressor gene promoters being hypermethylated among a host of other changes250. Thus,
in order to develop a holistic understanding of epigenetic changes in ITH, it is essential to identify
sequence specific changes in epigenetic modifications. The advent of gene specific targeting tools
such as CRISPR and TALE has made epigenomic editing and detection at specific gene loci
possible251–253. With respect to the detection of epigenetic signals at repetitive genomic loci, a
BiFC based approach has proven very successful171, but suffers from the usual drawbacks of the
BiFC strategy and a lack of quantitative accuracy. The development of the FRET platform in this
work perfectly positions us to improve upon the quantitative aspect of epigenetic detection by
using a CRISPR or TALE based tool for DNA sequence detection and our probes for epigenetic
modification detection. Initial results are promising by using a TALE based probe for identifying
repetitive DNA at centromeres and telomeres. However, the ease-of-use and versatility of the
CRISPR technology has made TALEs largely redundant. Future efforts would be worth expending
in using CRISPR for specific loci identification in combination with our probes.
Lastly, though we have mainly focused on applying the probes in the context of ITH,
epigenetic modifications and heterochromatin undergo rapid changes during differentiation
processes as well254. The expansion of the probes to human embryonic stem cell lines will provide
an invaluable tool to identify epigenetic control of pluripotency and changes in pluripotent cells
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upon differentiation. Epigenetic heterogeneity in stem cell cultures is also well documented255–257
and our probes can be used to sort populations of heterogeneous cells using a FACS platform.
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